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ABSTRACT

Wilson, Gregory L. Ph.D., Purdue University, December 2015. Development And
Application Of Pseudoreceptor Methods. Major Professor: Markus Lill.

Quantitative Structure-Activity Relationship (QSAR) methods are a commonly
used tool in the drug discovery process. These methods attempt to form a statistical
model that relates descriptor properties of a ligand to the activity of that ligand compound
towards a specific desired physiological response. QSAR methods are known as a
ligand-based method, as they specifically use information from ligands and not protein
structural data. However, a derivation of QSAR methods are pseudoreceptor methods.
Pseudoreceptor methods go beyond standard QSAR by building a model representation
of the protein pocket. However, the ability of pseudoreceptors to accurately replicate
natural protein surfaces has not been studied.

The goal of this thesis work is to

investigate the necessary descriptors to map a protein binding pocket and a method to
accurately recreate the 3-D spatial structure of the binding pocket. In addition, additional
applications of existing pseudoreceptor methods are explored.
To identify the necessary descriptors to map a protein binding pocket, we
developed a program that decomposes the protein-ligand interaction surface from a large
number of ligand-bound protein crystal structures.

The binding pockets of the protein

xiv
structure are identified, and then the physico-chemical properties of the protein are
mapped onto the solvent accessible surface of the binding pocket. A number of 2-D
Gaussian functions are then placed onto this surface to model the protein’s physicochemical properties. We found that a small number of these Gaussians were able to
accurately replicate the properties of the protein.
With this knowledge, we then desired a means of accurately recreating the
binding pocket surfaces of proteins only the structures of their bound ligands. Typically
in pseudoreceptor methods either the average or combined solvent accessible surface of
the ligand set is used. To test this, we generated iso-level surfaces of the solvent
accessible surfaces of sets of ligands for which the co-crystallized protein structure is
available. We also tested additional sets of surfaces located beyond the ligand’s solvent
accessible surface. We found that any single surface was unable to accurately reproduce
the protein-ligand interaction surface, and multi-surface approach using numerous isosurfaces is needed to accurately represent the protein.
Finally, we explored the application of RAPTOR, an existing pseudoreceptor
method, to the problem of the prediction of Sites-of-Metabolism (SoM) for Cytochrome
P450s (Cyps). In our approach, we used RAPTOR as a means of discriminating between
active (correctly predicted SoM) docking poses of ligands from decoy (incorrect SoM)
poses. With our method, we achieved the highest reported rate of SoM prediction across
nine Cyp isoforms, with the best reported performance on seven of those nine isoforms.
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CHAPTER 1. INTRODUCTION

1.1

Combined Ligand-based and Structure-based Computer-Aided Drug Design

The majority of Computer-Aided Drug Design (CADD) methods can be divided into
two categories: ligand-based drug design, and structure-based drug design.

These

categories are named after the origin of the data used in the design procedure. Ligandbased drug design efforts are based off the analysis of the biological activities and chemical
properties of a set of ligands, and are often used when little to no information about the
structure of the target protein is available. A primary example of ligand-based drug design
would be the wide variety of Quantitative Structure Activity Relationship (QSAR)
techniques. On the other hand, when there is sufficient information about the threedimensional structure of the target protein, especially if an X-ray structure is available,
structure-based drug design methods are routinely applied in the drug development process.
These techniques focus on simulating the interactions of potential ligands with the protein
structure. Molecular dynamics or Monte Carlo simulation-based free energy methods and
protein-ligand docking simulations are major types of structure-based design techniques.
However, as the number of available protein-ligand crystal structures continues to rise, and
as more and more physicochemical and biological data for ligands is published, there is an
increasing number of systems where both ligand and protein structure data is available.
Thus, there is a growing trend of attempting to
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perform both ligand-based and structure-based drug design on the same protein system.
These efforts may be as simple as performing QSAR or pharmacophore studies and
docking on the same system, and there are a number of examples of such occurrences in
the literature1,2.

What we are focused on here, however, are integrated methods of

combining ligand-based and structure-based drug design concepts into a single technique.
Some of the earliest work on combining techniques from structure- and ligandbased design was the adaptation of the GRID program3,4 to ligand-based design leading to
the GRID-GOLPE approach5. The GRID method can be used on a protein structure to
identify hotspots of possible protein-ligand interactions, e.g. favorable interactions with
hydrogen-bonding or hydrophobic groups. In the GRID-GOLPE adaptation, GRID is
applied on a set of ligand structures binding to a common binding site. GOLPE 6 performs
the chemometric analysis by identifying the descriptors strongly correlating with biological
activity and generating a multivariate regression using those descriptors. The methods that
we will discuss in this section cover two major categories where significant development
of integrated structure-based and ligand-based drug design is occurring: interaction-based
methods, like GRID-GOLPE, and docking-similarity based methods (Figure 1.1).
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Structure-Based Design

Ligand-Based Design

Integrated Methods

Interaction-Based Methods

Docking-Similarity Methods

Models built by identifying key
protein-ligand interactions
subsequently used for similaritybased screening

Models built by assessing
similarity of
shape/structure/interactions of
docking poses

Pseudoreceptors

Pharmacophores/
Fingerprints

Screening by
combining docking
and similarity-based
approaches

Integration of
similarity in
scoring of
docking poses

Figure 1.1: Classification scheme of integrated structure and ligand-based methods. The
major classification into two major categories includes interaction-based and docking
similarity-based methods. Each of those categories contain two subcategories:
pseudoreceptor methods and pharmacophore/fingerprint-based methods for the
interaction-based methods, and combined structure-ligand based virtual screening
approaches and methods that integrate similarity-based concepts into the scoring process
of ligand docking.
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1.1.1 Interaction-Based Methods
One major class of methods integrating both ligand-based and structure-based drug
design methods is based on comparing or modeling protein-ligand interactions across
similar protein-ligand systems.

These concepts seek to identify key protein-ligand

interactions from known data and utilize this interaction data to identify ligands with
similar interaction profile. This class of integrated methods can be further divided into two
sub-categories (Figure 1.1). The first sub-category is the pseudoreceptor techniques that
correlate similarities between ligands with measured biological activity, similar to QSAR,
but then use this data to establish a structural representation of the protein-ligand binding
pocket11,45,46,48,50-72. The other set of techniques is the converse of the first category. These
methods analyze protein-ligand interactions in structural data to extract key types of
interactions, and then translate that information into a simplified mathematical
representation that can be used by similarity-based methods to screen for active lead
compounds in ligand libraries73-96. Many techniques from this category are based upon
fingerprint or pharmacophore models.

1.1.2 Docking and Screening Based Methods
The second major class of integrated structure-based and ligand-based design
techniques is those methods which combine structure-based docking techniques with
ligand-based similarity information (Figure 1.1)2,97-104. The first subcategory is screeningbased methods.

These methods use ligand similarity to aid high-throughput virtual

screening in one of two ways. When there is a known hit or lead compound, similarity
studies are used to enrich ligand libraries to reduce the number of compounds that are
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docked. The other approach is to use docking to identify a possible hit, and then screen a
ligand library for similar ligands as alternative hits. The other category addresses one of
the major known issues with docking, the scoring problem, by integrating ligand similarity
directly into the scoring process.

1.2

Pseudoreceptor Methods

As mentioned previously, pseudoreceptor methods are a means of integrating
structure-based and ligand-based techniques.

Pseudoreceptor7 methods are primarily

expansions of Quantitative Structure Activity Relationship (QSAR) techniques, mainly 3D-QSAR techniques such as CoMFA8, CoMSIA9,10, or GOLPE6, that place
physicochemical information onto 3-D space surrounding a set of aligned reference
compounds that bind into the same binding site of a common macromolecular target.
Pseudoreceptor methods expand this mapping by attempting to create models of the target
protein binding site around the ligand ensemble. These representative pseudoreceptor
models are intended to contain key protein-ligand interactions, and to map these
interactions into an appropriate shape and volume.
The aim of generating these models is to be able to rationally modify or propose
new small molecules that are complementary to the pseudoreceptor model and to
accurately predict binding affinities for a series of potential ligands. Early pseudoreceptor
methods involved the manual folding of peptide chains around the ligand ensemble 11, but
these methods have now been expanded into a wide-variety of automated computational
methods. There are several major classes of pseudoreceptor methods including atom-based,
surface-based, fragment-based and residue-based methods1-6.
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1.2.1 Challenges of Pseudoreceptor Methods
Two critical factors in the overall process of pseudoreceptor modeling are the
chemical space of the ligand set and the ligand alignment process. The chemical space of
a ligand set refers to the set of physicochemical properties present in the entire ligand
library and the span of related binding affinities. The pseudoreceptor model can only
account for those features present in the chemical space of the ligand library, e.g. if a
protein has a hydrogen-bonding residue in the binding pocket with no matching functional
group in the ligand set, the pseudoreceptor model will lack that particular hydrogenbonding feature.
The alignment of the ligand set plays an important role in generating the
pseudoreceptor model as well. In order to accurately represent the 3-D structure of the
protein-binding pocket, the correct ligand binding mode is necessary. This is a non-trivial
challenge, especially with regards to highly flexible ligands. As such, a large number of
methods for alignment have been developed and utilized for the various pseudoreceptor
methods.

Alignment techniques include pharmacophore based methods, molecular

simulations, other similarity-based methods, as well as docking methods if protein structure
information is available12-21.

1.2.2 Surface-based methods
One major class of pseudoreceptors is surface-based methods, where the
pseudoreceptor is represented as a curved 3-D surface with physicochemical properties
mapped onto it representing protein properties important for protein-ligand interactions4448

. These surfaces are generated in a number of ways. In Receptor Surface Models (RSM),
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a “shape field” for each ligand is generated that represents the molecular volume 45-47. The
fields for all ligands are then combined, and an iso-level surface is generated based on the
combined shape field. In RAPTOR, an iso-surface approximating the solvent-accessible
surface of the aligned ligand-set is generated48. The occupancy of every ligand atom is
mapped onto a grid according to a smooth function ranging from one at the atom center to
zero at its solvent accessible surface. An iso-level surface is then generated again, similar
to the RSM approach.

1.3 Cytochrome P450
Cytochromes P450 (CYPs) are a superfamily of membrane-bound hemoproteins.
They are enzymes, with a heme-iron catalytic site with the iron coordinated via a cysteine
residue. CYPs, generally, catalyze the oxidation of a substrate via electron transfer and
hydrogen abstraction. CYPs are membrane-anchored proteins, with molecular weights
ranging from 45 to 60 kDa, and they contain large, flexible binding pockets. While CYPs
are found in a wide variety of species, the human cytochromes are encoded by 57 genes
and 33 pseudogenes and are divided into 42 families and subfamilies.49
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1.3.1 Importance of Cytochrome P450
CYPs metabolize both endogenous and exogenous compounds22, which leads to
their clinical importance: the CYP superfamily is responsible for the metabolism of the
majority of pharmaceutical compounds23. Particularly important in drug metabolism are
CYP1A2, CYP2C9, CYP2C19, CYP2-D6, and CYP3A424.

As drug metabolism and

elimination are important factors in the drug discovery and development process, and CYPs
play a ubiquitous role in those processes, CYP-drug interactions must be kept constantly
in mind when developing new pharmaceuticals25. Common concerns are metabolic rate,
which is a key factor in therapeutic dosage, and the production of toxic metabolites, which
can cause the abandonment of otherwise promising drug candidates26. These concerns lead
to the desire of medicinal chemists for the ability to alter metabolic rate or by-product
production by changing the site of ligand metabolism via CYPs27,28.

1.3.2 Site of Metabolism Prediction
In order to alter the metabolism of a ligand by CYP, one must be able to predict the
ligands’ sites of metabolism (SoM). Computational tools have become widely used for the
prediction of SoM of CYP substrates27. As mentioned previously, computational methods
are divided into structure-based, ligand-based, and combined methods, and there exists
CYP SoM prediction tools that fall into all of these categories29,30.
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1.3.2.1 Ligand-based Site of Metabolism Prediction
Ligand-based

techniques,

as

mentioned

previously,

analyze

ligands’

physicochemical properties to predict the most likely site of metabolism. Such methods
include quantum chemical calculation-based reactivity prediction, such as SmartCYP31,
pharmacophore models, rule-based methods, and fingerprint methods32. While highly
efficient, these methods also ignore important considerations, namely the binding pose of
the ligand with its target CYP, as the most energetically favorable metabolic site may not
be located in proximity to the catalytic heme.

1.3.2.2 Structure-based Site of Metabolism Prediction
The converse to ligand-based techniques, structure-based techniques calculate
interactions between a ligand and a structural model of the CYP enzyme to determine the
likely SoM. Structure-based techniques include ligand docking and molecular dynamics
simulations33. These techniques attempt to predict if a ligand will bind a specific CYP
enzyme, and if so, attempt to determine the binding pose of the ligand and which ligand
atoms are in close proximity to the catalytic heme.

These techniques can be time

consuming, especially molecular dynamics simulations, and are highly dependent on the
accuracy of the scoring function or force field used in the simulations and require protein
structure models, which can be difficult to obtain, especially for membrane-bound proteins
such as CYPs.
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1.3.2.3. Combined Ligand-based and Structure-based Site of Metabolism Prediction
As mentioned previously, both ligand-based and structure-based methods have
significant weakness when predicting SoMs. This has led many groups34-38, including the
Lill group39, to attempt to combine both types of methods. These combined methods are
designed to utilize ligand-based information while being guided by structural constraints.
These methods are especially useful when multiple metabolic pathways exist for a
compound.

An exemplar of this situation is the compound Terbinafine, which is

metabolized by at least seven different CYP isozymes and results in multiple different
metabolites40. The complex interactions between reactivity and ligand-binding pose are
difficult to predict using structure-based or ligand-based information only.
The approach previously developed by the Lill group combined the NAT reactivity
model developed by Olsen et al.41 with ensemble docking. In ensemble docking, molecular
dynamics simulations are performed on a protein crystal structure to produce a diverse
ensemble of protein structures. The ligands of interest are then docked to every member
of the protein ensemble instead of a single crystal structure. This allows for protein
flexibility to generate a more diverse set of ligand binding poses. In our previous method,
instead of purely relying on the docking scoring function to determine the best scoring pose,
and therefore the predicted site of metabolism as determined by proximity to the catalytic
site, the NAT model was included as an additional scoring factor. This skewed the results
towards those poses with a reactively favored atom close to the metabolic heme, and
produced better predictive results than the NAT model or ensemble docking in isolation.
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1.4 Research Summary
The overall goal of my research is the application and development of the
advancement of combined ligand-based and structure-based techniques, namely
pseudoreceptor-based methods, with a focus on surface-based pseudoreceptors. While the
goal of pseudoreceptor methods is to produce a protein-like structure to interact with
ligands, there has been a lack of use of protein structural data in the guiding of the creation
of the pseudoreceptors. In Chapter 2, analysis of the interaction surface between protein
crystal structure and co-crystallized ligand for the refined set of the PDBbind database42,43
will be presented. These surfaces represent the ideal pseudoreceptor, as they map the true
interactions of protein and ligand, and the analysis will show that the majority of proteinligand interactions can be mapped by a few of Gaussian-based descriptors that have
parameters that fall into a small range of values. In Chapter 3, a means of tuning surfacebased pseudoreceptors to accurately replicate protein binding pocket topology as from
known binding ligands will be presented.
In Chapter 4, I will discuss the implementation of the refinement of our group’s
previous work on SoM prediction, which includes the use of a modified version of the
RAPTOR pseudoreceptor package. The modification was the inclusion of reactivity scores
from the SMARTCYP package as term in the RAPTOR scoring function. The motivation
for the inclusion of RAPTOR was as a means of generating a model which could reliably
select binding poses with the known SoM close to the heme of CYP. This method was
implemented as a means to counteract the difficulties arising from the large number of
poses generated by the ensemble docking process. The initial modeling was performed on
CYP2C9, but was later extended to eight other CYP isozymes.
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Wilson, GL.; Lill, MA. Integrating structure-based and ligand-based approaches for
computational drug design, Future Medicinal Chemistry, 2011, 3, 735-770.
Wilson, GL.; Lill, MA. Towards a realistic representation in surface-based
pseudoreceptor modelling: a PDB-wide analysis of binding pockets, Molecular
Informatics, 2012, 31, 259-271
Kingsley, LJ.; Wilson, GL.; Essex, ME.; Lill, MA. Combining Structure- and LigandBased Approaches to Improve Site of Metabolism Prediction in CYP2C9 Substrates.
Pharm. Res., 2015, 32, 986-1001.
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CHAPTER 2. AN ANALYSIS OF BINDNG POCKETS

2.1

Overview

Pseudoreceptor models are intended to contain key protein–ligand interactions,
and to map the appropriate spatial information content of these interactions. The aim
of pseudoreceptor modelling is to generate surrogates of the 3-D structure of the
protein binding site that can be used for structure-based drug design applications such
as virtual screening, rationally modifying or proposing new small molecules
complementary to the pseudoreceptor model, and predicting binding affinities of
potential ligands. Although several types of pseudoreceptor representations exist 1,2 ,
one popular class are surface-based pseudoreceptor models that represent the binding
site of the target protein by selected surfaces. Of particular interest is the solvent accessible surface, as it represents the 3-D-space most critical for the complementary
contacts between protein and ligand. Hydrogen bonds and van der Waals interactions
are particularly strong at the protein-ligand interface. Thus, these surfaces can provide
a rather complete representation of the protein-ligand contacts while reducing the
number of descriptors compared to grid-based approaches.
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The method RAPTOR11 is an example of a surface- based pseudoreceptor
approach. Additionally, RAPTOR accounts for both ligand and protein flexibility. In
general the RAPTOR algorithm works by distributing hydrophobic and hydrogen
bond properties representing the surrogate of the target protein onto a surface
surrounding an aligned set of ligand molecules until the interaction between these
surface properties and the ligands reproduces the experimental binding affinities of
the compounds. A scoring function is then utilized to measure the interaction strength
between surface properties and ligand atoms.
The critical question is how the different physicochemical properties are
distributed onto the pseudoreceptor surface. In methods such as RAPTOR the surface
is typically represented by several hundred points. In the most naïve approach those
points are treated independently from each other, and overfitting may occur during
optimization of the pseudoreceptor model. To reduce the number of descriptors in
RAPTOR, we defined patches of surface points that were empirically forced to adopt
similar physicochemical properties. The patch size and the transition between patches,
however, are user-defined and may not reflect accurately the distribution of physicochemical properties in experimental protein structures.
In this chapter, we address the question if the physico-chemical properties on
the solvent-accessible surface of experimentally determined protein structures can be
accurately modelled by a small number of surface descriptors. First, we analysed
binding pocket surfaces of a large set of experimentally determined protein-ligand
complexes and used 2-D Gaussian functions to fit the surface properties. The fitted
property values differ from the original values on average by 15-25%, and on average
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six Gaussian functions are necessary to model each surface property. These
descriptors will allow for a more realistic pseudoreceptor representation of the
binding site compared to our current empirical patching model implemented in
RAPTOR and limit the number of descriptors, thereby reducing the potential of
overfitting throughout the QSAR optimization phase.

2.2

Database Preparation

For our analysis of protein-ligand interaction surfaces the PDBBind Database3,4
was chosen, as it contains target protein structures co-crystallized with small molecule
ligands. The refined set of the PDBBind database, a set of protein-small molecule crystal
complexes manually reviewed for resolution, binding affinity data, protein amino acid
composition, and ligand molecular and common element composition criteria, was
prepared as input data to our Protein-Ligand Surface Interaction Analysis (PLSIA) program
(see next section). The REDUCE program5 was utilized to add missing atoms to the PDB
structures and to optimize the protein’s hydrogen-bond network by adjusting Asn, Gln and
His side-chain orientations, as well as the tautomeric and protonation state of His residues.
AMBER atom types and partial charges were then assigned to the optimized protein
structures using the AMBER036 force field parameter file. Parameters were not assigned
to the ligand structures as they are used solely for the definition of the binding pocket.
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2.3

PLSIA Algorithm

2.3.1 Surface Triangulation
The Protein-Ligand Surface Interaction Analysis (PLSIA) program operated by
loading each protein structure and generating a separate PDB file in which the ligand has
been removed. The pseudo-holo form was used for the calculation of triangulated surfaces
on the exterior protein surface and any cavity using the MSRoll program7. MSRoll uses a
rolling probe method to determine the solvent-accessible surface. The cavity or surface
closest to the ligand was identified using a distance calculation between the ligand atoms
and the closest surface points and was selected as the protein- ligand interaction surface.
In order to produce a surface with a larger number of smaller triangles, the tessellation
fitness parameter was set to 0.5 radians, the default settings were used for all additional
parameters.
MSRoll generated a triangulated representation of each exterior and cavity surface,
however, the triangulation is often heterogeneous, with triangles varying significantly in
size. The COALESCE program8 was used to regularize the triangulated surfaces.
COALESCE loads the MSRoll output and combines small triangles, those with edges with
less than half the average edge length (which is typically around 0.5 Å), and fixes dangling
vertices resulting in a smooth triangulated surface with similar triangle sizes. COALESCE
also standardizes the direction of the normal vectors of each triangle, always pointing away
from the protein. After this refinement, all triangle vertices more than 8 Å from any ligand
atom were removed.
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2.3.2 Protein Property Calculation
After identifying and isolating the binding pocket surface, the program PLSIA
determined the electrostatic, hydrogen bond, and hydrophobic field of the protein mapped
onto each triangle vertex. The results of these equations were parameterized such that an
output value of one is approximately one kcal/mol of interaction energy.

2.3.2.1 Electrostatic Calculations
In PLSIA a partial charge was assigned to each protein atom using the Amber03
force field. The Coulombic potential on each surface vertex, s, generated by the protein
atoms within 12 Å was determined by the following equation:
n

s
VCoul

i 1

qi
D rsi   rsi

(2.1)

Here, n is the number of protein atoms within 12 Å of the surface point s, qi is the partial
charge of protein atom i, and D(rsi) is the distance-dependent dielectric, which in this case
is rsi itself, and rsi is the distance between the vertex s and atom i.

2.3.2.2 Hydrogen Bond Calculations
All protein atoms capable of forming hydrogen-bonds were identified in PLSIA.
Next, the availability of the donors and acceptors to form protein-ligand hydrogen bonds
was determined. Donors and acceptors form intra-protein hydrogen bonds if there was a
complimentary hydrogen-bonding partner identified within 2.5Å and a maximum angle of
40 degrees between the donor hydrogen atom, donor heavy atom and the acceptor atom.
Any donor or acceptor atom occupied by intra-protein hydrogen bonds was not considered
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for further calculation of the hydrogen-bond fields on the protein surface. Accessible
hydrogen bonding protein atoms that were within 4 Å of a surface vertex were used to
calculate the hydrogen bond potential on the vertex point s using the following equation:



n

s
HB

V

  f Fermi rsi ; 0.5, 2.3  f Fermi  ;10o , 50o



(2.2a)

i 1

with

f Fermi x; a, b  

1

1  exp  1a x  b 

(2.2b)

Here, rsi is the distance between the vertex s and the hydrogen bond partner
(hydrogen for donor and heteroatom for acceptor), and  is the hydrogen bond angle.
For hydrogen bond donors, this angle is between the donor hydrogen atom, the donor
heavy atom, and the vertex. For hydrogen bond acceptors, the angle is between the
acceptor’s lone pair, the acceptor atom, and the vertex. The donor potential and
acceptor potential were determined separately, and a value for both was assigned to
each vertex. In addition, the protein atoms which provided the strongest contribution
to each vertex were identified and stored.

2.3.2.3 Hydrophobic Calculations
PLSIA assigned a partial logP value to each protein atom using the methodology
of Wildman and Crippen9. The overall hydrophobic field spawned by all protein atoms
onto each vertex s was computed using the following equation:
n

s
VHO
  log Pi  f Fermi rsi ;1.5, 2.5
i 1

(2.3)
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Here, n is the number of protein atoms within 3 Å of the vertex s, logPi is the partial
log P value of protein atom i, and rsi is the distance between the vertex s and atom i.

2.3.3 Gaussian Preparation
After the physico-chemical properties of interest have been mapped onto the vertex
points of the solvent-accessible surface of the protein, several calculations had to be
performed to project the 3-D surface onto a 2-D projection map allowing subsequent 2-D
fits using Gaussian network models (see section 2.2.6). First, an analysis of the
connectivity of the vertex points was performed to generate the Shortest Path Array (SPA).
This array was an NxN matrix, where N is the number of surface vertex points, describing
the shortest connectivity between two vertices along the edges of the triangulated surface.
The generation of the SPA involved the use of an NxN Edge matrix in which all vertices i
and j, that are connected via an edge of the triangulated surface were assigned a value of
one to their corresponding entries Edgei,j and Edgej,i in the Edge matrix. All entries Edgei,j
that corresponded to unconnected vertices i and j were set to zero. A brute-force search
along the connected edges between all vertices using the Edge matrix was used to calculate
the smallest number of edges separating two vertices, and this value was stored in the SPA.
Thus the SPA recorded the smallest separation between two vertices along the edges of the
triangulated surface.
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Figure 2.1: Possible paths for vertices separated by three edges. Central path which
illustrates the bisecting path algorithm is shorter than left path composed solely of edge
traveling.
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Next, the relative coordinates of the surface points in 3-D representation of the
protein surface were projected into a 2-D representation to allow for a fit with 2-D
Gaussian functions: PLSIA approximates the 2-D distance along the interaction
surfaces (Figure 2.1). This calculation was trivial for adjacent vertices (Figure 2.1,
points A, B), but became more complicated for more separated surface vertex points.
For all adjacent vertex points, the direct 3-D distance between the two vertex points
was calculated and stored.
For points (Figure 2.1, points A, C) separated by two edges (SPA = 2), the
following process was used: First, all intermediate points were identified that are
directly connected to the two target vertices (SPA = 1). Due to the triangulation of
the surface, some vertices shared two intermediate po ints (B, D). For those cases, the
distance between the two target vertices was defined by finding the point on the
intermediate edge point (E) that had the smallest sum of distances to the target vertices
(A, C). This distance was determined computing the smallest distance along the
triangulated surface between points A and C passing through 100 equally separated
points along the edge BD. This represented the shortest path along the triangulated
surface between the target vertices (A, C) for a given pair of intermediates (B, D).
This distance was computed for all vertices with SPA = 2, and the shortest distance
for each pair was stored. For points separated by successively higher SPA values, the
distance was determined by finding the shortest distance given a single intermediate
point: For vertices with 3 edge separations (SPA = 3; Figure 2.1, points A, F) all
intermediates with an SPA = 1 to a target vertex (e.g. CF, GF) and an edge with SPA
= 2 (e.g. AC, AG) to the other vertex were compared; for vertices with 4 edge
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separations of all SPA=3/SPA=1 and SPA=2/SPA=2 pairings were compared and the
shortest distance for each target vertex pair was stored. This procedure was then
generalized for larger edge separations.

2.3.4 Patching Process
Next, the surface was divided into patches that represent local maxima of the
physico-chemical properties that were subsequently fitted using Gaussian functions (see
section 2.2.6). This patching was accomplished by the following process: First, dependent
on the studied property, the maximum or minimum value of the property on a vertex was
identified, and this vertex was defined to be the origin of the first patch. Starting from this
origin vertex, the vertices with increasing separation from the origin were examined: First
all vertices with SPA=1, then SPA=2, etc. were examined to determine if they are added
to the current patch, until an empirically defined maximum edge separation of nine was
reached.
In order for a vertex to be included in the current patch, it must have fulfilled
a number of conditions: First, the absolute value of the property had to exceed a
certain minimum property value, set to 0.1 kcal/mol for all properties, except
hydrophobicity which was set to 0.05 kcal/mol. This condition was introduced to
limit the patches to those vertices that represent significant magnitudes of the
properties of interest.

This condition also allowed for the separation of the

electrostatic potential into patches with positive and negative values using zero, or
more precisely the region between -0.1 and 0.1 kcal/mol as boundary criteria. The
second condition was that a vertex must be connected by at least a single edge to a
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vertex already included in the patch definition. This condition was used to prevent
two nearby, but separated patches from being combined into a single patch. The third
condition for defining a patch was that it must contain at least four vertices, as that is
the minimum number of points required to fit a 2-D Gaussian containing four
variables (see section 2.3.6). Additionally, the hydrogen bonding parameters had a
fourth patching criterion: all members of a patch had to share the same strongest
contributing protein atom as identified in the property calculation process. This
condition aided in separating overlapping hydrogen bonding patches caused by
different hydrogen-bonding protein groups.

2.3.5 Coordinate Transformation
The final step prior to the Gaussian fit was the transformation of the 3-D
coordinates of the surface vertices of a patch to 2-D coordinates (Figure 2.2). The
following list details the process of this transformation.
1.

The center of the patch was defined as the origin (O)

2.

The normal vector of the origin (ON) was calculated by averaging the normal
vectors of all triangles of which O is a member.

3.

A transformation plane was defined by the plane that passes through O and is
perpendicular to ON.

4.

All other vertices of the patch were projected into this plane along the vectors
normal to the plane (e.g. C  C’ or A  A’).

5.

A reference axis for use with 2-D polar coordinates was defined by the vector
between origin O and vertex C’ closest to the origin point.
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6.

Using this reference axis and the normal vector of the plane, angles for each of the
projected vertices were determined (Figure 2.2).

7.

The surface distance between each vertex A and O was looked up from the data
calculated in section 2.2.3.

8.

A new point B’ was calculated for each A by moving the distance from step 7 along
the angle from step 6. (e.g. Point B’ has coordinates (DistOA, (A’OC’)).

9.

Using these polar coordinates each new vertex was translated into 2-D Cartesian
coordinates with the origin vertex O having coordinates (0, 0) for use as a reference
point (e.g. (Dist OA cos((A’OC’)), DistOA sin((A’OC’))) for vertex B)’.
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Figure 2.2: Projection of vertices on 3D surface patch into the 2D plane defined by the
origin vertex O (maximum or minimum property value) and its normal vector. 3D
vertices, e.g. A, are projected into the plane (A’) and are scaled to match the 3D
surface distance between O and A (B’).
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2.3.6 Gaussian Fitting Process
Once all surface vertices of the patch were translated into 2-D Cartesian
coordinate form (x,y), a standard multivariate fitting algorithms was applied to fit a
2-D Gaussian function to each patch:



f ( x, y)  A exp  ax  x0   2bx  x0  y  y0   c y  y0 
a

cos 2  sin 2 

2 x2
2 y2

2

b

sin 2 sin 2

4 x2
4 y2

2

c



(2.4)

sin 2  cos 2 

2 x2
2 y2

with σx representing one axis of the Gaussian, σy the remaining axis, θ is rotation of
the Gaussian axes with respect to the standard Cartesian axes, and A is the amplitude
of the Gaussian.
PLSIA used the non-linear least-squares fitting algorithm from the GNU
Scientific Library10, based on the Levenberg-Marquadt algorithm, to fit a standard 2D Gaussian function to each patch. The fitting process was run for 10000 steps and
was repeated for up to 81 different initial parameter settings.

Each parameter,

amplitude, θ, σx, and σy, had three possible initial settings: 0.25, 0.75, 1.5. Different
permutations of these starting parameters were run until the Gaussian fit converged
to a solution with a low sum square error (the average percent error across the patch
is less than 10%) or until all 81 initial parameter sets had been evaluated, in which
case the run producing the smallest error was selected.
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2.3.7 Iteration and Re-patching Process
After fitting the first patch, the patching and fitting process continued according to
two different schemes. In the first scheme, called One Pass Fit patching, all vertices of the
previously fitted patch were removed from further consideration for subsequent patching
and Gaussian fitting. The patching and fitting process was repeated for all remaining
vertices until no further vertices meet the patch criteria. In this scheme, each point was
fitted to a Gaussian function at most once for any studied physico-chemical property.
The second scheme, called Residual Fit patching, allowed for each vertex to
be fitted multiple times. This was done to see if the surface was more accurately
represented by one patch per property per surface region or multiple overlapping
patches. This occurs by subtracting the physico-chemical values of the Gaussian fit
from the original value for every vertex of the current patch resulting in residual
values. These residual values were then assigned to each vertex and the modified
vertices were further considered in the patching algorithm as viable candidates.

2.3.8 Clique Detection Analysis Using Patch Centers
The Gaussian functions fitted to the patches model the physico-chemical properties
of the protein projected onto its surface. We expect similar properties on the surface for the
same protein bound to different ligands if no significant conformational change occurs. To
test this hypothesis, we performed clique detection between the patch centers for each pair
of proteins. The center points of the Gaussian fits produced by the PLSIA program were
considered as pharmacophores representing protein properties An edge array for each
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protein surface was generated storing the distances and center types (e.g. donor-donor,
donor-acceptor, etc.) for all pairs of centers.
These arrays were used in a clique detection algorithm performing an
exhaustive search to identify the maximum number of patch centres for which all
pairwise distances between the two proteins match. A distance between two centers
was considered a match if the distances for the two proteins were within a user defined tolerance of 0.75 Å and if the centers had matching corresponding property
types. A score S was computed for each pair of proteins i and j to measure the number
of common patch centers in the maximum common clique:
S ij 

nijcenters

(2.5)

min( nicenters , n centers
)
j

where n ijcenters is the number of matching centers in the clique and nicenters is the
number of centers for protein i. The number of matching centers was normalized by
the smaller number of total centers of the two compared protein in order to correct for
the variation in binding pocket size due to variation in size of the co-crystallized
ligands.

2.4

PLSIA Results

2.4.1 Quality of Fit
We used the following measure for evaluating the quality of the fits of the PLSIA
algorithm:
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(2.6)

n

C
i 1
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Ep represents the average relative deviation over n evaluated vertices for a property p
between the fitted values Fi at vertex i and computed initial surface value Ci at vertex
i. We used this criterion to evaluate two different analysis schemes using PLSIA, One
Pass and Residual Fit, as described under Section 2.3.7.
Table 2.1 displays the average relative error of Gaussian fitting for
electrostatic, hydrophobic and hydrogen properties. For electrostatic and hydrophobic
properties, the average error is approximately 15% of the initial surface values,
however larger errors are observed for donor and acceptor properties. This suggests
that the patches can be represented by single Gaussians.

We propose that this

difference in fitting accuracy between hydrogen-bond and the other properties is at
least partially due to the directionality of the hydrogen bond (Figure 2.5). If the
hydrogen bond is oriented along the normal vector of the surface, the resulting patch
is well characterized by a symmetric function such as the Gaussian function, as with
increasing surface distance from the center of the patch both distance and angle
increase reducing the interaction potential according to equation 2.2. However, if the
hydrogen bond direction is tilted with respect to the surface normal (Figure 2.5), the
distance and angle term in equation 2.2 display different maxima on the surface and
the resulting interaction potential on the surface will become asymmetric.
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Table 2.1: Average Relative Error of Gaussian Fitting for Individual Properties
Algorithm

El.st.

H.phobic

Donor

Acceptor

One Pass Fit

0.159

0.156

0.254

0.225

Residual Fit

0.158

0.144

0.238

0.210
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Figure 2.3: Hydrogen-bond interaction potential on the surface using equation 2
together with the optimal Gaussian fit to that distribution for a single hydrogen bond
group tilted with respect to the surface normal by 45 degrees. The hydrogen bond
group is located two units below the axis at x=0. The angle causes the potential
function to have maximum not located at the coordinate center (x=0). The error using
equation 5 is approximately 10% .
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We also observed that for all properties there is only a small differenc e in average
relative errors between the One Pass and Residual fits. Additionally, we investigated
the effect of two central variables in the program, the minimum and maximum sizes
of the fitted surface patch, onto the observed error in fit. The absolute minimum size
of a patch is four points, as that is the number of unknown variables in the Gaussian
function. Changing the minimum size (Table 2.2) showed significant variation in the
error of the fits. Some of the error is due to several small patches that are being less
well fit by Gaussian functions when a larger patch size is enforced. Consequently, we
chose a minimum size of four points for subsequent analysis.
The maximum size of the property patch is governed by the maximum number of
edge lengths measured from the surface point representing the maximum value of a
property of a patch. We investigated maximum edge lengths of five to nine edges
using the Residual Fit method.

Comparing the results across all properties, no

significant variation in observed error can be noted, as shown in Table 2.3. The aim
of this study was to investigate if a small number of surface descriptors can be used
to characterize the distribution of physico-chemical properties of the protein. Thus,
we decided to allow patches with maximum edge length of nine, as this would prevent
the splitting of large patches into smaller fractions, resulting in a decrease in number
of surface descriptors.
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Table 2.2. Average Relative Error of Gaussian Fitting for Individual Properties with
Variation of Minimum Patch Size (Residual Fit). Maximum edge length was set to
eight.
Type
interaction

of Minimum Points

El.st.
H.phobic
Donor

4
0.158
0.144
0.238

8
0.166
0.166
0.270

12
0.169
0.185
0.299

Acceptor

0.210

0.231

0.242
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Table 2.3: Average Relative Error of Gaussian Fitting for Individual Properties with
Variation of Maximum Patch Size (Residual Fit). Minimum number of points in patch
was set to four.
Maximum edge length

Type of
interaction
5

6

7

8

9

El.st.

0.141

0.148

0.153

0.158

0.158

H.phobic

0.138

0.141

0.141

0.143

0.144

Donor

0.240

0.240

0.238

0.238

0.238

Acceptor

0.210

0.209

0.209

0.209

0.210
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2.4.2 Characterization of distributions of properties
We characterized how the different physico-chemical properties are
distributed on the surface by analysing the size of the patches, and the magnitude and
widths of the fitted Gaussian functions. Here we considered the results from the
Residual Fit analysis.
Figure 2.4 shows that the largest portion of patches are small in size, with a
maximum number of patches with a size between four and ten (~1-3 Å2) for all
properties except hydrogen bond donors which adopts a broad maximum at a patch
size containing about 20 surface points (~5 Å2 ). The frequency of obtaining large
patches decreases rapidly with size for electrostatic and hydrogen bond properties,
however this trend is weaker for hydrophobic properties. Compared to hydrogen bond
properties, the interaction potential for hydrophobic contacts (equation 2.3) has a
longer interaction range. Furthermore, the hydrophobic function doesn’t contain any
directionality information, thus the hydrogen bond patches are more localized and
consequently smaller in size compared to the hydrophobic patches. Electrostatic
interactions are dependent on the partial charges, which for formally neutral chemical
groups are due to differences in electronegativity of bonded atoms. The connected
atoms in those groups typically have alternating signs of partial charge. On the
contrary, hydrophobic moieties in the binding site of protein consist of a collection
of connected atoms. Thus, it is not surprising that hydrophobic surface patches are
larger in dimension than electrostatic patches from neutral chemical entities.
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A

B

C

D

E

Figure 2.4. Distribution of number of patches with a specific patch size for
electrostatic (A, negative, B, positive), C, hydrophobic, D, hydrogen bond donor and
E, acceptor properties.
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A

B

C

D

Figure 2.5: Distribution of width of Gaussian fit to patches with electrostatic (A,
negative, B, positive), C, hydrophobic, D, hydrogen bond donor and E, acceptor
properties.
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A

B

C

D

E

Figure 2.6: Distribution of amplitude of Gaussian fit to patches with electrostatic (A,
negative, B, positive), C, hydrophobic, D, hydrogen bond donor and E, acceptor
properties.
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The trend for the distribution of patch sizes for the different physico -chemical
properties is reproduced in the distribution of the width of the Gaussian function fit
to the patches (Figure 2.5). Width has been defined as half of the sum of the lengths
of the principal axes of the Gaussian function. Compared to electrostatic and
hydrogen-bond properties, hydrophobic patches are on average larger in size and
consequently Gaussian fits display larger widths.
Figure 2.6 displays the distribution of amplitudes of the Gaussian fits for the
various properties. Interestingly, on average the negative electrostatic potential is
smaller in magnitude than the positive electrostatic potential. This reflects the smaller
van der Waals radius of partially positive hydrogen atoms compared to partially
negative nitrogen, oxygen, sulphur or carbon atoms. Thus, surface points on the
solvent accessible surface are on average closer to positive atoms than to negative
atoms, which results in stronger positive electrostatic potential compared to negative
potential. Most hydrogen bonding patches have amplitude of around one or minus one
consistent with the maximum hydrogen bond strength of one according to equation
2.2. Hydrogen-bond acceptor patches with amplitude up to two and donor patches
with amplitude up to three have been identified. Those patches represent surface
regions that share multiple nearby hydrogen-bonding functional groups of different
amino-acid residues that cannot be cleanly separated by the closest protein atom
classification.
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2.4.3 Similarity of binding sites
We also investigated how similar the identified patches and Gaussian fits were
for different crystal structures of the same protein. For this study, we ran the PLSIA
program on a set of structures for 4 different proteins: Estrogen receptor, CDK2, HIV
protease, and RARγ. The estrogen receptor set includes both protein structures with
bound agonists and antagonists. We performed a clique detection analysis of the
distances between centers of the surface patches (see section 2.2.8) for all pairs of
protein structures. The results were evaluated for pairs of structures of the same
protein system and different protein systems (Figure 2.7).
For the RARγ and agonist-bound estrogen receptors, there is clear separation
between the similarity scores (equation 2.5) for comparisons between structures of
the same protein system with respect to comparisons to structures of other protein
systems. Such a clear separation was not identified for the other protein systems,
though for CDK2 and HIV protease the intra-protein scores are slightly higher relative
to the comparisons with the structures of other protein system. For antagonist bound
estrogen-receptor structures, a separation to comparisons with other protein systems
is observed but not to comparisons with agonist-bound estrogen structures. This is not
surprising, as the antagonists bind also to the agonist binding site but their chemical
structure typically extends to a solvent-exposed moiety. As the used similarity
measure (Equation 2.5) is normalized to the minimum number of patches in either of
the two compared protein structures (here the agonist bound structures), the partial
overlap of agonist and antagonist binding sites resulted in a comparable range of
similarity scores.
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Figure 2.7: Similarity score (Equation 2.5) for all pairs of protein structures using
clique detection on the centers of surface patches. Each column represents all pair wise interactions for the indicated protein groupings, either intra or inter-protein.
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Analysing each individual protein structure (Figure 2.8) reveals that in all
cases the average similarity score to any protein structure from the same protein class
is higher than the corresponding average score to any other protein structure. Thus,
the analysis still seems to preferentially select members of the same protein class
against other protein systems, even for CDK2 and HIV protease.
Visual comparisons of pairs of protein structures of the same protein system,
reveals that low similarity scores are often associated with conformational changes in
the binding site (Figure 2.9). The structures of the binding sites of agonist-bound
estrogen receptors are relatively similar, resulting in comparable locations of the
Gaussian centers and consequently large similarity scores. In contrary, the CDK2
system shows significant conformational variation in the binding pocket, which leads
to dissimilar Gaussian center locations and low similarity scores.
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Figure 2.8: Difference in average similarity score (equation 2.5) between
comparisons to protein structures within and without the same protein class for all
protein structures. Positive values correspond to larger similarity among members of
the same protein class. Every individual protein structure was more similar to
members of its protein class (represented by a positive score) than to other protein
classes. The more rigid or conserved the binding pocket, the more positive the score.
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Figure 2.9: Pairwise comparison of Gaussian centers for two protein structures for
two different protein systems, agonist-bound estrogen receptor (top) and CDK2
(bottom). Top: Binding site residues for the estrogen receptor structures 1gwr (black)
and 1gwq (grey) are displayed as lines, the corresponding Gaussian centers are shown
as small solid spheres (1gwr) and large transparent spheres (1gwq). The binding site
residues don’t display significant conformational changes, resulting in similar
positions of Gaussian centers. Bottom: The extended loop regions in 1rej (black) and
1b38 (grey) show significant conformational differences resulting in poor overlap
between Gaussian centers of 1rej (small solid spheres) and 1b38 (large transparent
spheres). Gaussian centers for electrostatic negative patches are colored cyan, positive
(pink), hydrophobic (brown), donors (blue) and acceptors (red).
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2.5 PLSIA Conclusions
In this chapter we studied if the physico-chemical properties of the binding site of
a protein can be accurately represented by surface descriptors modelled by 2-D Gaussian
functions fitted to surface patches. Properties such as electrostatic and hydrophobic
properties are accurately fitted using Gaussian functions with an average relative error
around 15%. Hydrogen bond properties are more localized but display larger errors around
20-25% compared to other properties. One contribution to this increased error is that
hydrogen bonds are directional but the vector of directionality of a hydrogen bond donor
or acceptor doesn’t necessarily point in the direction of the surface normal. Adding a
directionality term to the Gaussian fit function may reduce the error of fit but increases the
number of fit variables and consequently the potential of overfitting.
The type and location of the Gaussian centers is consistent among different structures
of the same protein system, if no significant conformational changes are observed in the
binding site upon binding of different ligands. On average, only about six Gaussian
function descriptors are necessary to model each physico-chemical property important for
ligand binding. This demonstrates the potential to use 2-D Gaussian functions in surfacebased pseudoreceptors allowing for a significant reduction of number of descriptors in the
QSAR modeling process.
***Note: Portions of this chapter previously published in:
Wilson, GL.; Lill, MA. Towards a realistic representation in surface-based
pseudoreceptor modelling: a PDB-wide analysis of binding pockets, Molecular
Informatics, 2012, 31, 259-271
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CHAPTER 3. OPTIMIZING SURFACE REPRESENTATIONS OF BINDING
SITES USING EXPERIMENTAL PROTEIN-LIGAND STRUCTURE DATA

3.1 Overview
As mentioned in Chapter 1, there are several major classes of pseudoreceptor
methods including atom-based, fragment-based and residue-based methods1,2. One major
class is surface-based methods, where the pseudoreceptor is represented as a curved 3-D
surface with physicochemical properties mapped onto it representing protein properties
important for protein-ligand interactions3-6. These surfaces are generated in a number of
ways. In Receptor Surface Models (RSM), a “shape field” for each ligand is generated that
represents the molecular volume3-5. The fields for all ligands are then combined, and an
iso-level surface is generated based on the combined shape field. In RAPTOR, an isosurface approximating the solvent-accessible surface of the aligned ligand-set is generated6.
The occupancy of every ligand atom is mapped onto a grid according to a smooth function
ranging from 1 at the atom center to 0 at its solvent accessible surface. An iso-level surface
is then generated again, similar to the RSM approach. Atom-based approaches use similar
methods to determine where to place the atoms of the pseudoreceptor7-11. For example,
FLARM generates a spherical grid around the geometric center of the aligned ligands8.
The sphere is then contracted towards the center until a grid point contacts the surface of
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a ligand atom. The surface is finally relaxed to allow for a cushion distance of less than
one Å between ligand and pseudoreceptor. In WeP 11, the marching cube algorithm is used.
The space surrounding the ligand set is divided into cubes and steric overlap of a methyl
groups (2.0 Å probe radius) placed on each cube vertex with the ligands is tested. The
interacting cube vertices are then used for generating a triangulated surface representing
the pseudoreceptor.
Whereas those different schemes aim to empirically reproduce the surface of the
binding site using ligand information only, to the best of our knowledge, no systematic
investigation was performed to validate which surface generation process most accurately
reproduces the surface of the real binding site of experimentally determined protein-ligand
structures.
In general, experimental information about the protein structure is not used to
generate a pseudoreceptor. In this study, however, we will use experimental data to
optimize the pseudoreceptor method to accurately represent the binding pocket for any
given protein. We studied a number of protein-ligand crystal structures for three different
protein systems and investigated whether the molecular surface of the protein structure can
be reproduced with iso-surfaces generated from the corresponding co-crystallized ligands.
Throughout our analysis, we have identified a set of parameters that reliably reproduces
the surface of the binding pocket for all studied protein systems.
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3.2 Methods
3.2.1. Protein Surface Generation
For the protein-surface analysis 35 protein-ligand structures from three protein
systems were selected from the Protein Data Bank (PDB) (www.rcsb.org)12: 20 cyclindependent kinase 2 (CDK2) structures, 7 estrogen receptor  (ER) structures, and 8 HIV
protease (HIV-PR) structures. (Table A1) The crystal structures within each protein system
were aligned to each other using PyMOL. The molecular surface of each protein binding
pocket was then identified using MSRoll in conjunction with our previously described
refinement algorithm13. (Figure 3.1a) For ER, surface points with a maximum distance of
4 Å to any ligand atom was used; for CDK2 and HIV-PR this cut-off was set to 5 Å. The
lower cut-off for ER was necessary to prevent the inclusion of surface points in our analysis
that result from cavities other than the binding pocket.

3.2.2. Occupancy Calculation
The crystal structure ligands were extracted from the aligned PDB structures and
grouped into five categories: ER, HIV-PR, CDK-20, CDK-10, and CDK-5. The ER, HIVPR, and CDK-20 groups contain all ligands for each respective protein system, while CDK10 and CDK-5 are randomly chosen subsets of the CDK-20 group made up of ten and five
ligands respectively. A grid around the aligned ligand molecules was constructed using
the minimum and maximum x-, y- and z-values, (xmin, ymin, zmin) and (xmax, ymax,
zmax), respectively of any atom of the ligand set plus an additional 10 Å cushion in each
positive and negative direction. Grid points were placed starting from (xmin, ymin, zmin)
using a grid-spacing of 1 Å.
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Figure 3.1: Schematic of algorithm: (a) Generation of triangulated protein surface. Red
triangles and lines are vertices and edges of triangulated MSRoll surface. Blue circles
represent grid points generated in subsequent steps. (b) Occupancy of ligand molecules
mapped to grid. Occupancy of ligand 1 (pink) and ligand 2 (green) are calculated on grid
points. Occupancy is averaged across all ligands to produce final value (black). (c) Isosurfaces of ligand occupancy are generated. Occupancy values are interpolated between
grid points to match a target iso-level. These vertices are then used to generate an isosurface shell of ligand occupancy. The solid black line represents the 0.1 occupancy isosurface, the dashed line the 0.7 occupancy iso-surface. (d) Interpolation of protein surface
occupancy. Protein surface points (red triangles) are placed inside the grid generated from
their corresponding crystal ligands (blue circles). The ligand occupancy values of these
grid points are then interpolated to generate occupancy values for each protein surface point
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The steric occupancy of the ligand atoms were then mapped onto the grid. These
occupancy values represented the shared volume there would be between a sphere placed
on the grid point with the molecular (van der Waal’s) volume of a ligand atom, with a value
of one representing full overlap, and zero indicating no overlap. Occupancy was calculated
with the same function as used in the RAPTOR QSAR package6:
4

𝑑 6

17

𝑑 4

22

𝑑 2

𝑂 = 1 − (9 ) ∗ (𝑀 ) + ( 9 ) ∗ (𝑀 ) − ( 9 ) ∗ (𝑀 )

𝑑<𝑀

𝑂=0

𝑑≥𝑀

(3.1)

𝑀 = 𝑟𝑣𝑑𝑊 + 𝑐
Where O is the occupancy, d is the distance between ligand atom and grid point, and M is
the maximum radius. The maximum radius for a ligand atom is defined as the van der
Waal’s radius rvdW of that atom plus a constant value c. In this work, four different
constants were used: c = 1.4 Å, 2.0 Å, 2.5 Å, and 3.0 Å. (Figure 3.2) The 1.4 Å constant
reflects the solvent accessible surface (SAS) of a ligand, as the occupancy function reaches
zero at the SAS radius using this constant.
For every ligand molecule, the occupancy for each atom was computed on all grid
points within 4 Å plus the van der Waals radius of the atom. (Figure 3.1b) The highest
atom occupancy for every given grid point was stored as the final occupancy value for the
ligand molecule. In the cases of the 1H00 structure for CDK2, there were two ligand
conformations present, so the occupancy values for the grids of the two conformations were
averaged to give a final occupancy for that ligand.

The occupancies for all ligand

molecules within a set were then averaged to produce a final occupancy for each grid point
representing the full ligand group.
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Figure 3.2: Occupancy as function of distance with varied values of c. Function begins at
a value of one at zero distance and decays to zero at a distance equal to the sum of the van
der Waals radius of an atom plus a constant c. In this graph, the van der Waals radius is
set to 1.5 Å for all value of c
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3.3. Analysis
The occupancy grid was used for the final two steps of the analysis: comparison
with the protein surfaces and construction of iso-surface shells. For a given iso-level, the
iso-surface was constructed using the marching cubes algorithm14. First, the occupancy
grid was searched in a systematic manner, starting with the origin point of the grid (xmin,
ymin, zmin). The seven vertices surrounding this point in the positive x, y, and z directions
were identified and used to generate a cube. If all eight vertices of the cube have occupancy
values higher or lower than the target iso-level, the cube was discarded and the next cube
was searched. This process continued until the full grid had been searched and all
occupancy values mapped.
When a cube had at least one vertex with occupancy higher than the target iso-level
and at least one vertex with occupancy lower than the target iso-level, it was identified as
a “surface cube” at a given iso-surface level. The marching cubes algorithm then
determines the intersection of the target iso-surface with the cube. This was done by
interpolating where the edges of the cube intersect with the iso-surface. These intersections
are then used to determine one or more surface triangles representing the target iso-surface.
These triangles were then stored, and once all cubes had been searched, combined into a
single triangulated iso-surface shell of the ligand occupancy. This is illustrated in Figure
3.1c. The grid in the figure has been divided into four squares representing cubes of the 3D grid, and two example iso-surfaces. The 0.1 iso-level value iso-surface passes through
the top two squares, as they have lower vertices greater than 0.1 and upper vertices less
than 0.1, just as the 0.7 iso-surface passes through the bottom squares for the same reason.
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An iso-surface with target value between 0.35 and 0.65 would pass through all four squares,
as each has at least one vertex above and one vertex below that value.
The final process of the algorithm was to compare the known protein surfaces
generated from the crystal structures with the occupancy grid generated from the cocrystalized ligands of those structures. To achieve this, the surface points, generated from
MSROLL, for each protein structure of a set were placed into the generated occupancy grid
of the ligands. The eight grid vertices of the occupancy grid surrounding every surface
point were identified, and tri-linear interpolation was used to determine the occupancy
value at the coordinates of the surface point. (Figure 3.1d) This value represents which
iso-surface shell of the ligand would pass through each given protein surface point. This
process was repeated for every protein structure of a given set.
Histograms were generated to determine how well an iso-surface a given iso-level
is able to reproduce the experimental protein surface. The histograms measure the percent
of protein surface points that are spatially congruent with the iso-surface at a given isolevel of occupancy displayed on the x-axis of the graphs. When discussing the graphs,
coverage percentage refers to the percent of protein surface points that would be contained
within an iso-surface shell of a given iso-level. Cumulative occupancy graphs were
generated to display the coverage percentage.

3.4 Results
The primary focus of this study is to derive an optimized algorithm to generate
pseudoreceptor surfaces that closely mimic the experimental binding pocket surface of
protein structures using the co-crystallized ligands. To achieve this end, we performed
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both a quantitative as well as a qualitative analysis of the results of our algorithm,
generating the following results for the individual protein systems.

3.4.1 Estrogen Receptor
Figure 3.3 shows the histogram results for the surface comparison analysis using
the four different constants c for the ER protein set. The results for the 2, 2.5, and 3 Å cvalues show similar profiles. The higher c-value histograms show shifts towards higher
average occupancy values. This is due to the fact that once a surface point lies within the
maximum distance of the occupancy function an increase in the c-value will simply result
in an occupancy value closer to one. There are slight differences between these three
constants: instead of the single maximum in the histogram using c = 2.0 Å, for c = 3.0 Å
there is a small additional maximum at lower occupancies. This feature starts to appear in
the c = 2.5 Å statistics. This is most likely caused by ligand variation. One ER ligand is
significantly different from the rest, with a group occupying a unique region of space. This
difference causes a large variation in the protein surfaces, and causes the double maxima,
as there are two distinct surface profiles. For c = 1.4 Å, a significantly different profile is
observed with a small number of points located outside the maximum distance:
approximately 0.15%. This means that these points are located more than the c-value plus
van der Waal’s radius away from any ligand atom. The width of the histogram peak is also
very compressed, with 25% of points located between occupancies of 0 and 0.15 with the
maximum located in the bin between 0.05 and 0.10 occupancy.
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Figure 3.3: ER occupancy distribution graph with varying values of c in occupancy
calculation. Occupancy values are binned in .05 width increments, starting with 0.025 as
a bin center representing the 0-0.05 bin and increasing to 0.975. Bins are inclusive on the
upper limit, exclusive at the lower limit. An additional zero bin is added which includes
the fraction of protein surface points with no mapped occupancy
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Figure 3.4 shows the cumulative histogram for the ER system. Of particular interest
are the occupancy bounds for the majority of the surface points (i.e. finding the ligand isosurface shells that would surround the majority of surface points. For c = 1.4 Å, 93% of
protein surface points have interpolated occupancies higher than 0.05, and 74.4% higher
than 0.10. On the other tail, only 1% of points have occupancies higher than 0.65, 6%
higher than 0.45, and 13% higher than 0.35. Together, this means 80% of surface points
are located between 0.05 and 0.35 occupancy, 90% between 0.05 and 0.55 and 99%
between 0 and 0.65. For the other values of c, the occupancy iso-levels with the same
percent coverage increase with c-value. This occurs through all coverage percentages,
increasing with greater iso-level values, leading to an increase in the difference of iso-level
values between any two coverage percentages. For example, 94% of points have higher
occupancies than 0.1, 0.15, and 0.2 for the 2.0, 2.5, and 3.0 Å constant values, respectively.
The 5% coverage iso-levels are for these runs: 0.6, 0.7 and 0.75. So the total separation
for the iso-surface shells containing between them 90% of protein surface points increases
from 0.5 occupancy difference for 1.4 Å to 0.55 for the 3.0 Å run. The 99% separations
are much larger: 0.65, 0.8, 0.85, and 0.9 for the 1.4 Å, 2.0 Å, 2.5 Å, and 3.0 Å c-values.
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Figure 3.4: ER accumulation graph with varying c-values in occupancy function. Y-axis
is percent of total protein surface points with iso-level of less than or equal to the x-axis
bin. Bins are determined in the same manner as the corresponding distribution graph
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3.4.2 HIV-PR
The results for HIV-PR are shown in Figure 3.5. The results for this system follow
similar trends to the ER system. The distribution profile for c = 1.4 Å is significantly
different from the other three c-values. New profile features start developing when c = 2.0
Å, and these features develop fully in the 2.5 Å and 3.0 Å runs, which show very similar
profiles. A major difference between the results for HIV-PR as compared to ER is that it
is not until c = 3.0 Å that all surface points have a higher than 0 occupancy. This is partly
expected, as the distance cut-off for protein surface points is 1 Å larger for the HIV-PR and
CDK systems. While the percentage of uncovered surface points is relatively high, 5%,
for c= 1.4 Å, it decreases to 1% and then to 0.08% for c = 2.0 Å and c = 2.5 Å. The bimodal
motif that was partly evident in the ER set is much more pronounced in the HIV-PR set
when c= 2.5 and 3.0 Å, with a swift increase at low occupancies that plateaus for a
significant range of occupancies, and then increases to a maximum followed by a decrease,
as seen in Figure 3.5.
The accumulation results for the HIV-PR set are shown in Figure 3.6 and Table A5.
For c= 1.4 Å a significant fraction of points have low occupancies. 20% of protein surface
points have occupancy less than 0.05. 99% of points have occupancy lower than 0.55, 95%
lower than 0.45, and 90% lower than 0.35. For c = 2.0 Å, 99% of points have occupancy
> 0.0, and 90% have occupancy higher than 0.05.
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Figure 3.5: HIV-PR occupancy distribution graph with varying values of c in occupancy
calculation. Occupancy values are binned in .05 width increments, starting with 0.025 as
a bin center representing the 0-0.05 bin and increasing to 0.975. Bins are inclusive on the
upper limit, exclusive at the lower limit. An additional zero bin is added which includes
the fraction of protein surface points with no mapped occupancy
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Figure 3.6: HIV-PR accumulation graph with varying c-values in occupancy function. Yaxis is percent of total protein surface points with iso-level of less than or equal to the xaxis bin. Bins are determined in the same manner as the corresponding distribution graph
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3.4.3 CDK
In this work, three different sets of CDK2 ligands were used to produce occupancy
data: CDK-20, CDK-10, and CDK-5. CDK-10 is a subset of CDK-20 and CDK-5 is a
subset of CDK-10. In the analysis stage, however, all twenty protein structures were used
for all three ligands sets. This was done to determine how well the iso-surface shells from
a smaller ligand set correspond to the larger ensemble of protein structure. Figure 3.7 and
Tables A6-A11 show the results for the individual sets. (Occupancy accumulation graphs
for CDK are not shown) Whereas the total range of occupancy values of the protein surface
points is similar in all sets compared to the HIV-PR and ER system, there is a notable shift
in the distribution of occupancy values towards higher median occupancies for all c-values
higher than 1.4 Å. This shift in average occupancy increases with the size of CDK set,
with the CDK-5 set having the lowest median occupancy and CDK-20 the highest.

70

Figure 3.7: CDK occupancy distribution graphs with varying values of c in occupancy
calculation for all three CDK systems. Occupancy values are binned in .05 width
increments, starting with 0.025 as a bin center representing the 0-0.05 bin and increasing
to 0.975. Bins are inclusive on the upper limit, exclusive at the lower limit. An additional
zero bin is added which includes the fraction of protein surface points with no mapped
occupancy. (A) CDK-5 set (B) CDK-10 set, and (C) CDK-20 set

71
Looking at the four different c-values across all three sets, there are a number of
similar trends. First, the larger the ligand set, the higher the maximum. Second, the smaller
the ligand sets the more surface points are located at the extreme occupancies: more points
with very low occupancy and more points with very high occupancy. For the high
occupancy points, this is due to the averaging occurring in the occupancy calculation. As
more ligands are included, with spatial and chemical diversity, the high occupancy isosurface shells decrease in volume. In addition, at very high iso-levels, approximately 0.9,
the algorithm fails to build a full continuous shell. This is due to the averaging process
across diverse ligands leading to low maximum occupancies. For example, if a set was
comprised of two non-overlapping ligands, the maximum possible occupancy would be 0.5
due to the averaging process. The reason for the higher number of very low occupancy
points is the inverse of this process. As long as a surface point falls within the cut-off
distance of a single ligand atom, it receives a non-zero occupancy value, even if the
averaging process makes it very small. This process shifts points to lower occupancies
overall, which results in the increasing maxima, which are located at low occupancy values
in all three CDK sets.

3.4.4 Iso-surface Shells
While looking at the previous histograms provides information on how many
protein surfaces points are covered by a given iso-surface shell, it does not provide the
whole story on the quality of the fit. For example, a 50 Å sphere centered on a ligand set
would likely provide 100% coverage, while being of poor use in pseudoreceptor modeling.
To address this issue, a number of iso-surface shells of the ligands were generated for visual
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inspection. Similar to the previous section, we wanted to investigate the effect of changing
the distance constant c, the number of ligands used in shell generation, and target iso-level
on the overall shape and size of the iso-surface. When referring to these figures, exterior
refers to the space that is located outside of the protein surface when viewed from the ligand
center; interior refers to the space inside the protein surface, respectively. The transition
region is the 3-D space where the protein surface points are located. (Figure 3.8)
Figure 3.9 shows the 0.05 iso-surface shell of the HIV-PR system at the four
different c-values. The overall shape of the shells is similar for each c-value, the primary
change being the spatial extension of the shell. Figure 3.13 also demonstrates how closely
the shells match the protein surface. Using c = 1.4 Å, the majority of the shell is located
slightly to the exterior of the protein surface points, but is in the transition region in some
portions. For c = 3.0 Å, even though the iso-surface shell is located almost exclusively to
the exterior, the shell is overall significantly larger than the protein surface.

The

intermediate c-value iso-surface shells fall between these two extremes, with decreasing
portions of the shell in the transition region, but with other regions located exterior to the
protein surface.

73

Figure 3.8: Definition of terms for discussion of iso-surface shells. Red triangles and lines
represent individual protein surfaces. Black lines divide space into three regions: exterior,
transition region, and interior. Interior refers to the region of space that is enclosed by all
protein surfaces, corresponding to the intersection of all protein binding pockets. The
transition region refers to the 3-D space where the varying protein surfaces are located.
The exterior is refers to the region of space that would be filled by the protein or bulk
solvent that surrounds the binding pocket
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Figure 3.9: 0.05 Iso-level shells for HIV-PR with varying c-values: (a) 1.4, (b) 2.0, (c) 2.5,
(d) 3.0. The iso-surfaces are generated using an iso-level of 0.05. Increasing c-value
results in an expansion of the shells. All sub-figures focus on the same region of the HIVPR binding pocket showing the larger shells including previously excluded protein surface
points in one portion while simultaneously diverging from the protein surfaces in another
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The effect of changing the number of ligands in the CDK systems is shown in
Figure 3.10. The shells shown represent the 0.05 iso-surface with c = 2.5 Å. Overall, the
three iso-surface shells are very similar. No shell is consistently larger than any of the
others, though there are regions where each shell is largest. However, as the size of the
ligand set increases, the curvature of the iso-surface shells becomes more refined, creating
a slightly more complex surface. This consistency is desirable, as it indicates that a small
ligand set can generate a pseudoreceptor that could be applicable to a larger set of ligands
as long as they cover similar space in the binding pocket. This is the case for the CDK
system we studied where the ligands of the CDK-5 set cover roughly the same 3-D space
when aligned as the full CDK-20 set.
Figure 3.11 shows the iso-surfaces of the ER system at varying iso-levels with c =
3.0 Å. The 0.05 shell encompasses nearly all of the protein surface points and follows the
contours of the protein surface. As the iso-level value increases, the encompassed volume
of the shells decreases. This decrease is most pronounced in the region indicated by the
red arrow in Figure 3.11b. This region is occupied by a single protein-ligand complex
(2P15), and receives a very low average occupancy value, and the 0.25 iso-surface shell
does not contain this region. The 0.5 iso-surface shell is mainly located in the transition
region of the protein surface points. At high iso-levels, such as 0.75, the shell is almost
completely to the interior of the protein surfaces.
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Figure 3.10: 0.05 Iso-level shells of CDK sets with c-value of 2.5 and iso-level of 0.05.
(a) Paired shells for CDK-5 (red) and CDK-10 (blue), (b) CDK-5 and CDK-20 (green), (c)
CDK-10 and CDK -20. While slight variations exist between all three shells, the overall
shapes of the shells are very similar between the three CDK sets
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Figure 3.11: Iso-surface shells of estrogen with c=3.0. Iso-levels are (a) 0.05, (b) 0.25,
(c) 0.5, (d) O.75. The size and shape of the iso-surface shell varies significantly with
change in iso-level. Most notable is the change between the 0.05 shell and the 0.25 shell
in the region indicated by the red arrow in sub-figure B. The protein surface points in
this region come from a single protein structure, giving the region a very low average
occupancy even where the ligand for that structure is located. This causes a dramatic
difference between the 0.05 shell, which includes the full region, and the 0.25 shell which
does not include the space
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3.5 Conclusion
As previously mentioned, the focus of our research was to determine a means of
producing a pseudoreceptor iso-surface that corresponds to the protein-ligand interaction
surfaces present in PDB crystal structures. To achieve this goal, we first investigated how
well the composite solvent-accessible surface (SAS) of a ligand set reproduces the protein
surfaces, as the SAS is used in a number of pseudoreceptor generation methods. We
approximate this surface by setting c=1.4 Å. At this value, the occupancy function decays
to zero when a grid point is 1.4 Å plus van der Waals radius away from a given ligand atom.
Therefore, any grid point with occupancy greater than zero would be within the typical
SAS, while grid points with zero occupancy are outside the SAS. The SAS covers the
majority of protein surface points. However, with the exception of the ER system, there
remained a small portion of surface points not contained within the SAS, with a minimum
coverage of 92% for the CDK-5 set. In addition, from visual inspection, the SAS isosurface shells with low (<0.05) iso-levels, are located in close proximity to the protein
surface. Conversely, increasing the c-value to 3.0 Å ensures nearly complete (>99%)
coverage, but the iso-surface shells included portions in 3-D space that would overlap with
the protein.
In order to create an accurate pseudoreceptor surface model, we need to find a
balance between achieving the maximum possible coverage of protein surface points and
smoothly approximating the protein surfaces without significant overlap with the protein.
Also, from visual inspection, coverage percentage may be misleading in certain cases.
When a protein binding pocket is solvent exposed, it is possible for surface points that are
within the distance cut-off to be in fact outside the binding site. (Figure 3.12) Due to the
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opposing geometries of the protein binding pocket which are concave and the generated
iso-surface which is convex, slightly lower coverage percentages are observed. This
underestimation must be considered in evaluating the results of the algorithm. From our
results, we would recommend a c-value of less than or equal to 2.0 Å, as higher c values
produce shells that are significantly larger than the protein surfaces at low iso-levels. For
these c-values, we recommend an iso-level target of <0.05, as these parameters result in
iso-surface shells that cover approximately 95% of protein surface points, while smoothly
approximating the protein surface in most regions.

80

Figure 3.12: Scheme for coverage percentage of solvent exposed ligand binding pockets.
Red triangles and line represent the protein surface of a single protein-ligand crystal
structure. Due to curvature where the pocket is solvent exposed, certain protein surface
are included within the distance cut-off of the algorithm that do not fall within the convex
ligand-iso-surface shell (dashed line)
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While the previous parameters for c and iso-level are useful in determining an isosurface shell that encompasses the full combined protein surface, this shell fails to address
a number of issues. First, ligand diversity can vastly increase the size of an iso-surface
shell constructed from a low iso-level target, as seen in the ER system, where there is a
vast difference between the 0.05 shell and the 0.25 shell due to a single ligand having a
pose which occupies a different region of the binding pocket compared to all other ligands.
In addition, the surfaces of the individual proteins vary significantly due to protein
flexibility, resulting in a wide range of mapped occupancies (>0.5 iso-level difference
range for 95% of protein surface points). With respect to pseudoreceptor modeling, this
means while the low iso-level iso-surface shell represents the outermost surface to all
ligands, it does not fully replicate the surface with which an “averaged” ligand would
interact, especially if the ligand set is diverse. This averaged surface would be represented
by an iso-surface shell closer to interior of the protein surface points, inside the transition
region. As seen in Figure 3.11, in the ER system the iso-level that corresponds to this
region is in the range of 0.5-0.6.
It is also important to note, that while the suggested parameters represent general
starting points, they will not be ideal for all protein ligand systems. In just the three systems
considered in this study, there are significant differences in the occupancy profiles of the
protein surface points. The flexibility of the protein and the diversity of the ligand set play
important roles in determining the ideal parameter set. A rigid system would lead to a
lower ideal c-value, as seen in the ER system, where even with c=1.4, less than 0.1% of
protein surface points do not have an occupancy value. Increasing ligand diversity leads
adjusting the iso-level targets of the interior and exterior shells. For example, with the
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CDK-20 set, it is impossible to create an iso-surface shell with iso-level greater than around
0.7, as the surface becomes discontinuous due to ligand diversity and the averaging process
in the occupancy calculation
These individual factors lead to a number of final conclusions. First, it appears to
be unlikely for a single pseudoreceptor surface to fully and accurately replicate the
individual protein binding pockets for a diverse ligand set. A low iso-level produces an
iso-surface shell that contains the surfaces for all ligands, but can vary significantly from
individual protein surfaces where there is diversity in a ligand set. Higher iso-level isosurface shells more closely reproduce the surface that an “average” ligand would see, but
lose the unique features of more diverse ligands. To address the drawbacks of the
individual surfaces, it may be advantageous to use an ensemble of pseudoreceptor surfaces.
RAPTOR implements a version of this with its dual-shell model6. In this model, two isosurfaces are built using the most affine ligand as the basis for the inner shell and all ligands
for the outer shell. We propose a similar solution, utilizing multiple shells of varied isolevels: higher iso-level shells would represent the conserved portions of the ligand, and low
iso-level shells would include the effects of ligand variation.
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CHAPTER 4. INTEGRATED STRUCURE AND LIGAND-BASED METHOD FOR
THE PREDICTION OF SITES OF METABOLISM OF CYTOCHROME P450
ISOZYMES.
***Note: This chapter was performed in collaboration with Dr. Laura Kingsley and
Morgan Essex. Dr. Kingsley and Ms. Essex were responsible for the method
development of the MD simulations, ensemble selection and generation, and docking,
and performed these studies on CYP2C9. Gregory Wilson was responsible for the QSAR
development and studies on CYP2C9. He also performed all studies for the remaining
CYP isozymes and is responsible for webserver development. Portions of this chapter
previously published in:
Kingsley, LJ.; Wilson, GL.; Essex, ME.; Lill, MA. Combining Structure- and LigandBased Approaches to Improve Site of Metabolism Prediction in CYP2C9 Substrates.
Pharm. Res., 2015, 32, 986-1001.
4.1 Introduction
As discussed in Chapter 1, our group has previously implemented a method that
combined ensemble docking and NAT reactivity scores in an integrated structure and
ligand-based tool for the prediction of CYP SoMs. The success of this approach was in
part attributed to the inclusion of critical binding site conformations during docking via
the use of a protein ensemble which led to a ~10% improvement in identifying reactive
ligand poses as compared to docking to the crystal structure alone 1.
While the inclusion of protein flexibility using an ensemble of protein structures
improved the generation of docking poses that were consistent with the experimentally
known SoM, the number and diversity of false poses also increased. This increase in
binding poses presents a significant challenge for the scoring functions used in docking
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and was thought to be the primary cause of the reduced prediction accuracy of docking
observed in the top-1, top-2 and top-3 positions1. The poor docking performance in the
ensemble is likely one of the key reasons that the improvement in SoM prediction
accuracy in the ensemble was only modest compared to using only the crystal structure1.
Based on our previous findings, we have developed a revised methodology to better
incorporate protein flexibility and to better rank predicted poses in CYP2C9. The two
main methodological improvements compared to our previous approach are a prefiltering process to reduce the size of the protein ensemble used in docking and the
implementation of pseudoreceptor modeling to accurately rank the binding poses relevant
for SoM prediction. Compared to the existing methods cited above, our approach differs
in method by which the data from docking and SMARTCyp2 are combined, namely a
modified pseudoreceptor scheme. To the best of our knowledge, this is the first attempt to
directly incorporate SMARTCyp reactivity data into a pseudoreceptor model that is based
on structural protein and ligand data to predict SoMs in CYP2C9.
A schematic of the revised procedure is shown in Figure 4.1. As with our previous
model, both structure- and ligand-based principles were used in the current scheme;
SMARTCyp, a successor of the NAT model was used to predict reactivity scores for each
atom and ensemble docking was used to incorporate structural features of CYP2C9. We
compared predictions in the crystal structure alone to predictions in a “pseudo-apo”
ensemble which was selected based on a pre-filtering step used to isolate structures
relevant for ligand binding. We found that incorporating “pseudo-apo” simulations
increased the conformational space covered by the binding pocket allowing for successful
docking of nearly all ligands. This was in stark comparison to the crystal structure alone,

86
where less than 65% of the ligands tested could be successfully docked. In this study, as
with our previous study, we noticed that the scoring function used in docking did not
always accurately predict the correct binding poses. Due to the difficulty of accurately
ranking poses using the docking scoring function, we introduced a pseudoreceptor model
to differentiate between poses. Using the poses generated by docking and the reactivity
scores generated by SMARTCyp, we produced a dataset suitable for pseudoreceptor
modeling. A modified, in-house version of the RAPTOR3 pseudoreceptor QSAR suite
was used to develop a pseudo-receptor model to identify docking poses that correctly
predict SoMs in our CYP2C9 ligand data set. With this approach we were able to
significantly improve SoM prediction in the CYP2C9 ligand data set tested. Using a
combination of docking to the pseudo-apo ensemble, SMARTCyp, and pseudoreceptor
we were able to accurately predict the SoM in 96% of ligands within the top-2 positions.
Afterwards, we extended this method to eight additional CYP isozymes and
obtained similar results. These isozymes are responsible for metabolism of significant
percentages of all drugs: 1A2 (15%), 2A6 (3%), 2B6 (8%), 2C8 (8%), 2C19 (12%), 2-D6
(25%), 2E1 (4%), and 3A4 (50%), along with 2C9 at 20% 4.
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Figure 4.1: SoM prediction using a combination of structure- and ligand- based approaches.
Using both atom reactivity data from SMARTCyp and structural data from docking, we
generated a set of active (true SoM is within 4Å of the reactive oxygen) and decoy poses.
A subset of these poses was used to train a pseudo-receptor QSAR model which was then
used to evaluate all docking poses of all ligands.
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4.2 Methods
4.2.1 CYP2C9 Ligand Library Preparation
A set of 73 structurally diverse CYP2C9 substrates with known SoMs were used
for this study (Table A12). The compounds were based on those used by Danielson et.
al(20), which were taken from the literature5 and the University of Washington Metabolism
and Transporter Drug Interaction database© (www.druginteractioninfo.org). All possible
stereoisomers (in case that stereochemistry was not defined for the structure) and relevant
protonation states were considered as unique chemical structures resulting in 139 total
ligand structures. Ligands were built using Maestro and minimized using MacroModel as
previously described1.

4.2.2 SMARTCyp
SMARTCyp2 is a reactivity model that predicts the reactivity at C, S, N, and P
positions in a given ligand based on a series of over 40 rules derived from quantum
calculations. SMARTCyp 2.4.2 was used to predict likely SoMs based on reactivity
energies and atom accessibility in each of the 139 total ligand structures. The atoms of each
ligand were then ranked according to the predicted abstraction energy, also referred to as
the SMARTCyp score. In cases where one or more ligand variants existed, for instance two
possible protonation states of the same ligand, the best (lowest) overall score was selected
for each atom. The percentage of correctly predicted SoMs in the top-1, top-2, and top-3
positions were calculated using the experimentally known SoMs. In cases where a given
substrate had more than one known SoM, only the highest predicted SoM was considered.
This criterion was also used for all subsequently described methods.
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4.2.3. Static Crystal Docking
The 1R9O crystal structure of CYP2C9 was used for the static docking studies.
The co-crystalized ligands, flurbiprofen and glycerol, along with all crystal waters were
removed. The crystallized heme (deoxygenated) was replaced by an oxygenated heme.
Protonation and tautomer states of histidine and rotamer states of asparagine, glutamine
and histidine were assigned using Reduce6. The ligand library was prepared for docking
using the PyMol plugin developed by Danielson et.al7.

4.2.3.1 Autodock Vina
Ligands were docked using AutoDock Vina (Vina). The docking volume was
defined using our PyMol plugin. The selected docking cuboid was roughly 20Å on each
side and included the active face of the heme and surrounding residues that could be
relevant for binding. Default values were used for all docking parameters in Vina. For each
unique ligand, 10 total docking poses were generated and 5kcal/mol was chosen as the
maximum energy difference allowed between the best and any other reported docking pose.

4.2.3.2. Ranking
Docking success was evaluated based on the distance between the known SoM and
the reactive oxygen of the heme moiety. Because docking to multiple similar protein
structures can result in redundancy of several ligand poses, the poses were clustered using
k-medoid clustering. K was iteratively adjusted such that the maximum RMSD between
any two poses and the cluster center was less than 1.0Å. The pose with the best (lowest)
docking score from each cluster was selected as the representative member for that cluster.
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Next, docking poses of all protonation states and stereoisomers of a given ligand
were pooled resulting in a single set of poses for each ligand containing all protonation and
tautomeric states of the ligand. The combined poses were then ranked according to the
docking score. If two poses had the same docking score, both would share the same rank,
but the rank immediately following would reflect the inclusion of multiple poses. For
instance assuming two poses had the same score and were ranked first, the next compound
would be ranked in the third position to account for the two ligands that had been previously
ranked higher.
A distance of 4.0Å or less between any heavy atom and the reactive oxygen was
considered to be potentially reactive. Poses that did not have a heavy atom within 4.0Å of
the reactive oxygen were omitted from the ranking scheme.
Next, each atom was assigned the best Vina docking score attained by any pose
wherein the atom was within 4.0Å of the oxygen on the heme. The atoms were then ranked
according to the assigned score and the percentage of accurately predicted SoMs that
occurred in the top-1, top-2 and top-3 positions was calculated. In addition to determining
the accuracy of SoM predictions in the top-3 positions, the overall docking success was
determined for docking to the crystal structure and the ensemble. The overall docking
success is defined as the percentage of ligands that could be successfully docked regardless
of ranking. In other words, the overall docking success is a measure of how well the pose
prediction portion of the docking algorithm performed exclusive of the scoring function.
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4.2.4 Ensemble Generation
4.2.4.1 MD Simulations
An MD simulation of the pseudo-apo structure of CYP2C9 was used in the
ensemble generation process. To generate the initial protein structure the ligand was
removed from the CYP2C9 crystal structure, 1R9O.
The MD simulation was performed using Gromacs-4.5.58,9 and the Amber03 force
field. The input structure was prepared using Reduce6 to identify the proper rotamer,
tautomer, and protonation states of histidine, and the proper rotamer states of asparagine
and glutamine. The heme parameters were extracted from the literature 10. We opted to use
an oxygenated heme model because the oxygen may be critical for the docking of certain
ligands. Gromacs was used to solvate the system in an octagonal water box of SPC216
waters and 6 chlorine ions were added to neutralize the system. The box size was selected
to guarantee a minimum distance of 15Å between solute and box edge.
The steepest descent method and particle mesh Ewald (PME) summation with a
grid size of 0.12nm was used to carry out 1000 steps of energy minimization. To compute
van der Waals interactions a switching function was applied between 1.0nm and the cutoff of 1.4nm. The LINCS algorithm11 was used to constrain bonds containing hydrogen
atoms. Next the hydrogen bond network of the surrounding waters was established using a
200ps MD simulation in which all but the waters were restrained. Simulations were
performed at 300K using PME, Berendsen thermostat, and Parrinello-Rahman pressure
coupling. The integration time step was 2fs. Finally a 400ps equilibration run was
performed to equilibrate the system prior to the 10ns production run.
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4.2.4.2. Ensemble Generation and Refinement
The initial ensemble was generated by extracting frames every 100ps from the
pseudo-apo production run. The initial ensemble was then refined using a docking-based
filtering process resulting in a 6 member ensemble. From the 73 ligands used in this study,
14 structurally diverse ligands (denoted in Table A12) were manually selected for
ensemble refinement. These 14 ligands were docked to all members of the 100-member
ensemble using AutoDock Vina, as described above. Ligand variants were combined to
give a single set of poses for each ligand as previously described.
To determine which protein structures were able to best dock the 14-ligand training
set, a fitness score was calculated for each protein structure as follows:

14−𝑙𝑖𝑔𝑎𝑛𝑑 𝑡𝑟𝑎𝑖𝑛𝑖𝑛𝑔 𝑠𝑒𝑡

𝐹𝑖𝑡𝑛𝑒𝑠𝑠 =

∑𝑖=1

𝑤𝑖 𝑓𝑖
14−𝑙𝑖𝑔𝑎𝑛𝑑 𝑡𝑟𝑎𝑖𝑛𝑖𝑛𝑔 𝑠𝑒𝑡
∑𝑖=1
𝑤𝑖

5;
𝑟𝑎𝑛𝑘 = 1
4; 2 < 𝑟𝑎𝑛𝑘 < 4
𝑓𝑖 = 3; 4 < 𝑟𝑎𝑛𝑘 < 6
2; 6 < 𝑟𝑎𝑛𝑘 < 10
{ 1;
𝑟𝑎𝑛𝑘 > 10 }

(4.1)

Where wi is one over the number of protein structures to which the ligand i was successfully
docked and fi represents an assigned value based on the docking rank. Poses that were not
successfully docked (e.g. did not have the known SoM within 4Å of the reactive oxygen)
were given a score of 0, while those that were successfully docked were given a score
between 1 and 5, based on the rank of the pose. The factor wi guarantees that protein
structures are more likely selected for the refined ensemble that allow the successful
docking of ligands that are difficult to dock. For example, assume that two ligands A and
B dock successfully to protein structure S. Assume ligand B is successfully docked to 49
other protein structures (out of 100 structures in the initial ensemble) and ligand A is only
docked successfully to S. As protein structure S seems to be unique and relevant for binding
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ligand A and structurally similar ligands, it should gain a high fitness value and be more
likely to be included in the refined ensemble. This is achieved by the introduction of the
weight (wi) which will be 1.0 (1/1) for ligand A but only 0.02 (1/50) for ligand B.
The protein structures from the ensemble were then ranked by fitness. We found
that 13 out of 14 ligands could be successfully docked to at least one of the top-5 ranked
protein structures. The remaining ligand, 2-oxoquazepam, was not successfully docked
until the 34th ranked protein structure. Based on our previous findings that the inclusion of
multiple protein conformations can be problematic for the docking scoring function, we
felt that including 34 structures would be detrimental to the model. We tested the top-4,
top-6, top-8, and top-10 protein structures on the entire ligand data set (data not shown)
and found that selecting the top-6 structures achieved optimal template diversity.

4.2.5. Ensemble Docking
All 139 ligand structures were docked to the 6-member protein ensemble. Ensemble
docking was performed in a similar fashion as to the static crystal docking described above.
Again, all ligand variants from all ensemble members were pooled to produce a single set
of poses for each ligand, the resultant poses were clustered and the cluster member with
the highest docking score was selected.

4.2.6. Ranking
As with the static crystal docking, the atoms of each ligand were ranked according
to the best docking score in which that atom was within 4.0Å of the reactive oxygen. The
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percentage of successfully predicted SoMs in the top-1, top-2 and top-3 positions were
calculated as well as the overall docking success, as described above.

4.2.7. SMARTCyp + Docking
In an attempt to improve SoM ranking in the top-1, top-2, and top-3 positions, we
combined SMARTCyp reactivity predictions with the docking results. A single combined
score (CS) was calculated for each atom of a given ligand using the following function:
𝐶𝑆 = 𝑅𝑖 + 𝛾𝑆𝑖

(4.2)

where Ri is the atom’s SMARTCyp reactivity score (usually ranging from about 50 (best)
to 100(worst)) and Si is the docking score from the highest ranked pose where the atom i
was within the 4.0Å cutoff from the oxygen of the heme (usually ranging from about -12
(best) to -6 (worst)). Gamma (γ) is a weighting factor between 0 and 10, and is used to
adjust the contribution of the docking score (Si) to the total combined score (CS). In order
to be further considered in the CS scheme, an atom had to have both a docking score and a
SMARTCyp score, otherwise the atom was omitted as a potential SoM.
Gamma was optimized using a subset of ligands (denoted in Table A12) and the following
fitness function:
𝑓𝑖𝑡𝑛𝑒𝑠𝑠 = (%𝑡𝑜𝑝1) + 0.5(%𝑡𝑜𝑝2) + 0.25(%𝑡𝑜𝑝3)

(4.3)

Where %top1, %top2, and %top3, reflect the percentage of accurately predicted SoMs in
the top-1, top-2 and top-3 positions, respectively. Gamma was initially set to 0 and was
iteratively increased by 0.5 to a maximum of 100. The gamma value that maximized the
fitness score for each data set (i.e. crystal or pseudo-apo ensemble) was selected.
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For each ligand, atoms were ranked by CS value. As with the docking scores, atoms
with equivalent CS values were ranked at the same position, but the next position reflected
the inclusion of multiple atoms at the previous position. The percentage of correctly
identified SoMs in the top-1, top-2 and top-3 ranked atoms was calculated for the x-ray
crystal structure alone and the pseudo-apo ensemble.

4.2.8. SMARTCyp+ Docking+ QSAR
In an attempt to further improve SoM prediction results we implemented a modified
QSAR scheme to evaluate and re-rank docking poses. The SMARTCyp score and free
energy of binding were combined into the fitness functions used for deriving the QSAR
model.

4.2.8.1 Dataset Preparation and Selection
As described previously, SMARTCyp assigns reactivity scores to all ligand atoms,
with the lowest score representing the predicted SoM. When combining the SMARTCyp
reactivity approach with docking, the SoM predictions can be re-ranked by including only
those atoms within a reactive distance of the oxygen atom of the heme. The main limitation
of this approach is the accuracy of the docking scoring function. Often poses are found in
which the true SoM is within the cutoff distance (active poses), but these poses may be
amongst the worst ranked by the scoring function. This problem intensifies as more poses
are introduced using ensemble docking. To overcome the limitations of docking scoring
functions, we developed a modified version of the RAPTOR QSAR package to generate a
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statistical model to differentiate poses that are consistent with the experimentally known
SoM from those which are not.
The clustered docking poses were used as input for the QSAR model (Figure 4.2a).
The poses were first separated into active poses and decoy poses (Figure 4.2b). An active
pose was defined as a pose in which the known SoM was docked within 4Å of the oxygen
on the heme and had the known SoM within the top-3 ranked SMARTCyp scores for those
atoms within 4Å of the heme oxygen atom. The active poses were further classified by
whether the known SoM had the first, second, or third best SMARTCyp score (Figure 4.2c).
A decoy pose was defined as any pose that was docked with at least one atom within 4Å
of the heme oxygen atom but did not meet the criteria for an active pose.
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Figure 4.2: Scheme of QSAR modeling process. First the poses generated by docking
(a) were separated into active and decoy poses and the actives subcategorized into Top 1,
Top 2, and Top 3 actives(b). A driving force (DF) was then assigned to each pose (c) and
the RAPTOR package was used to generate a QSAR model(d). After the QSAR training,
all poses for a ligand are sorted by the QSAR score (e) and atom scores are assigned to
the top three SMARTCyp atoms for each pose. Atoms are then ranked by the final score
(FS) according to the QSAR model (f).
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4.2.8.2. Test and Training Selection
A random set of nineteen ligands was selected as the initial test set for the QSAR
simulations and the remaining ligands were assigned to the training set. The value of
nineteen was chosen as this represented approximately one-quarter of the available ligands
for QSAR modelling. The test set was then manually curated to ensure that it covered the
chemical space of the training set. During this evaluation, four of the test ligands were
moved to the training set, and an equal number of ligands were moved to the test set to
retain the overall 3:1 training to test ratio. Two of the ligands that were moved into the
training set had unique ring structures not found in any other ligand in the data set, a third
ligand had a unique long carbon chain, and the final ligand was the smallest compound in
the data set. These unique features cause the ligands to be unsuitable for the test set. This
test set was then used for all remaining QSAR simulations. The final training and test sets
are noted in the “Data Set” column of Table A12.
As discussed earlier, active poses are further classified based on the rank of the
SoM using the SMARTCyp score. Thus, for many ligands there are binding poses in which
the SoM is ranked as most reactive atom (i.e. other more reactive atoms are not within 4Å
of the catalytic center) and other poses where the SoM is ranked lower (e.g. as top-2 or top3) because in addition to the try SoM, other more reactive atoms also fall within 4Å of the
reactive oxygen. In a strict sense, the later poses disagree with the experimental SoM data
and would add noise to the QSAR training process. Thus, during QSAR model training
only the active poses with the highest ranked SoM based on the SMARTCyp score were
used as active poses. All other active poses, however, were moved into the final prediction
set which contains all docked poses with any atom within 4Å of the catalytic oxygen. This
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prediction set was used for final evaluation of SoM prediction quality using our optimized
QSAR model (Figure 4.1, last step).

4.2.8.3 Inclusion of SMARTCyp reaction scores
To directly incorporate the SMARTCyp scores into the QSAR model, the RAPTOR
package was modified. The original version of RAPTOR uses hydrogen-bond interactions
and hydrophobic contacts between the ligands and the pseudo-receptor generated by
RAPTOR to predict binding affinities. In the modified version of RAPTOR, the
SMARTCyp score was provided as an additional contribution to the overall predicted score.
Thus, the QSAR score Qscore was computed by the sum of hydrogen-bond interactions
ΔGHBond, hydrophobic contacts ΔGHPhob and SMARTCyp score SSMARTCyp:
𝑄𝑠𝑐𝑜𝑟𝑒 = ∆𝐺𝐻𝐵𝑜𝑛𝑑 + ∆𝐺𝐻𝑃ℎ𝑜𝑏 + 0.1 ∙ 𝑆𝑆𝑀𝐴𝑅𝑇𝐶𝑦𝑝

(4.4)

SMARTCyp scores were assigned to every pose as 1/10th of the original value to
scale the reactivity scores to the same order of magnitude as the other two contributions to
the Qscore within the RAPTOR models. For active poses, the SMARTCyp score of the
known SoM was used. For decoys, the lowest SMARTCyp score of any atom within 4.0Å
of the oxygen atom of the heme was used.
Also, the input to the QSAR method was adjusted (Figure 4.2b). Typically, all
poses for a given ligand are treated as alternative conformations of the same ligand and the
experimental affinity value is used during the QSAR modeling process for every
conformation. For our method, we grouped active and decoy poses separately. In addition,
instead of binding affinities, the active poses were assigned a negative score, while the
decoys were assigned a score of 0 or a positive value. We will refer to the difference
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between these scores as a “driving force.” The goal of this driving force is to identify the
physicochemical features in the QSAR model that allows discrimination between active
and decoy poses due to differences in protein-ligand interactions.
In order to determine the optimal driving force, we ran multiple RAPTOR
simulations with different driving forces. We ran simulations with both a fixed driving
force for all active poses, and simulations with a variable driving force for the actives. For
the variable driving force simulations, the top-1 actives poses are assigned a value of X-Y,
top-2 poses are scored as X, and top-3 poses are scored as X+Y where X and Y are real
floating point values ranging from -5 to -2 and Y ranging from -1.5 to -0.5. Using variable
weights for top-1, top-2 and top-3 poses improved the performance of the QSAR model
compared to assigning identical weights to all actives. Many of the driving force weights
generated QSAR models with similar quality. Therefore, we chose a set of weights in the
middle of our testing range, i.e. an X value of -3 and a Y value of 1, with the decoy set
being assigned a value of zero. This setting had the best performance by a slight margin.

4.2.8.4 QSAR Modeling
The modified RAPTOR program was used to generate a pseudo-receptor QSAR
model for CYP2C9 with all remaining parameters set to their default values.

Five

individual models, run with the fast search mode, a coupling factor of 0.5 and sharpness
penalty of 1 were constructed for each modeling run.
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4.2.8.5 Analysis of QSAR Results
Typically, pseudo-receptor models are used to predict the binding affinity of a
ligand. RAPTOR, in addition to providing an overall prediction of the affinity of the ligand,
predicts the binding energy for each conformation of a ligand. In this study, those
conformations are the individual docking poses for a ligand. However, here the predicted
score does not provide an estimate of the binding affinity but yields a likelihood score for
each conformation to be the pose predicted to have the known SoM within 4 Å of the
catalytic center. To evaluate the success of our model, all binding poses of training and test
set were combined with the predictive set of actives excluded from the modeling process.
The trained QSAR model was used to assign QSAR scores to all poses which were then
ranked by this score (Figure 4.2e). The atoms within 4Å of the catalytic center with the
top-3 SMARTCyp scores for each pose were assigned modified QSAR scores using the
following formula:
𝐹𝑆𝐴 = 𝑄𝑠𝑐𝑜𝑟𝑒 +

𝐶𝑌𝑃𝐴 −𝐶𝑌𝑃𝑅𝐸𝐹
10

(4.5)

where FSA is the final score for atom A, Qscore is the QSAR score for the pose in which
atom A is found, CYPA is the SMARTCyp score for atom A, and CYPREF is the
SMARTCyp score for the atom used in the QSAR model building process . This formula
adjusts the QSAR score for the difference in SMARTCyp scores between the top three
SMARTCyp atoms (Figure 4.2f). The lowest score for any given atom among all poses
was identified, and then the atoms themselves were sorted by score. The highest ranked
known SoM was identified and the percentage of correctly predicted SoMs in the top-1,
top-2, and top-3 positions were reported.
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4.3 CYP2C9 Results and Discussion
4.3.1 SMARTCyp Prediction
Several reactivity schemes have been developed to predict SoMs in CYP substrates
based on the physicochemical properties of the ligand alone2,12. Such ligand-based methods
are advantageous because they do not require protein structural information and are
computationally efficient. SMARTCyp is one example of a widely used reactivity based
method. Potential SoMs are evaluated based on a combination the accessibility of the atom
within the structure and the estimated energy required to abstract a hydrogen from carbon
atoms or for an oxygen attack in the case of nitrogen, phosphorus, and sulfur atoms. The
resultant score is referred to as a SMARTCyp score and is used to rank potential SoMs.
Recently, a new version of the SMARTCyp program, version 2.4.2, was released with
parameters specific to CYP2C9 ligands13.
We generated a 139-ligand data set comprised of all possible rotameric and
protonation states of 73 unique ligands and evaluated each using SMARTCyp version
2.4.2 (referred to as SMARTCyp). The atoms of each ligand were ranked according to
the assigned SMARTCyp reactivity score and the number of correctly predicted SoMs in
the top-1, top-2, and top-3 positions was calculated (Table 4.2 - SMARTCyp Alone
column). SMARTCyp correctly predicted the known SoM at the top-1 position in 42% of
the ligands tested. In the top-2 and top-3 positions, the prediction percentages increase to
58% and 67% respectively.
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4.3.2. Static Docking
Docking is another approach used to predict potential SoMs in CYP ligands.
Docking is one of the most widely used techniques in structure-based drug design and
provides information about potential ligand binding modes. In the biologically active
conformation within the CYP binding site, the ligand should be positioned in such a way
that the SoM is in close proximity to the reactive oxygen atom of the heme moiety. In
theory, if the docking pose is correctly predicted, atoms which are positioned near the
oxygen atom of the heme are the most likely SoM candidates.
As a comparison to our new approach, we docked our ligand library into the
crystal structure of CYP2C9 (PDB ID: 1R9O) using Autodock Vina (Vina). A docking
pose was considered to be an accurate SoM prediction if the distance between the known
SoM and the reactive oxygen of the heme moiety was 4Å or less. Docking poses were
ranked by the internal Vina scoring function and the percentage of correctly predicted
SoMs in the top-1, top-2, and top-3 ranked poses were calculated (Table 4.2 - Vina Alone
column). In addition to assessing predictions in the top-3 ranked poses, we calculated the
overall docking success by determining the percentage of ligands that achieved an active
pose regardless of rank (Table 4.2- Vina Alone column).
SMARTCyp outperformed docking in identifying the known SoM within the top3 positions. However, the overall docking success was approximately equal to the
prediction success of SMARTCyp in the top-3 positions (64% and 67% respectively). This
highlights two possible shortcomings in the standard Vina docking approach. First, despite
67% overall accuracy in docking, less than half of these poses were ranked in the top-3
positions, suggesting that the Vina scoring function does not always rank potentially
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biologically active conformations in the top positions. Second, the failure to achieve 100%
docking success suggests that the binding pocket of the crystal structure alone may not be
able to accommodate the structural diversity of the ligands in the data set.
It is well known that CYP enzymes are highly flexible and that the binding sites of
these enzymes often have to adapt to accommodate structurally different ligands 14. The
plasticity of the CYP binding sites can make docking to these enzymes challenging and
often ensemble approaches are employed to improve docking results15,16.

4.3.3 Ensemble Generation and Selection
4.3.3.1 Ensemble Diversity
A pseudo-apo ensemble was generated by extracting 100 snapshots from a 10ns
trajectory of CYP2C9 with the crystal ligand removed. A principle component analysis
(PCA) suggests that through the duration of the simulation, both the overall protein
structure and the binding site residues adopted several alternative conformations (Figures
4.3a and 4.3b). Ultimately, the increased diversity in the pseudo-apo ensemble allowed for
improved docking of several ligands in comparison to the crystal structure.
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Figure 4.3: Principal component analysis of CYP2C9 pseudo-apo MD trajectories. The
PCA using all protein residues (a) and only the binding site residues (b). The binding site
residues were manually defined based on the defined binding site box from the docking
simulations. The black circles represent the top-6 structures selected for the final ensemble.
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For instance, no active docking pose was found for 9-cis-retinoic acid in the crystal
structure, however side-chain rotations that occurred during the pseudo-apo simulation
allowed for successful docking of this ligand (Figure 4.4a). The orientation of LEU 208,
PHE 476, and PHE 100 ( PHE 100 was omitted from figure for clarity) are crucial to
achieve a bioactive conformation of this ligand. In the crystal structure, the top-ranked
bioactive pose of the ligand directly overlaps with LEU 208. Furthermore, the rotation of
ASP 293 in the pseudo-apo simulation provides a potential hydrogen bonding site for the
ligand.
Additionally, the binding of torsemide required a significant rearrangement of
residues in the active site (Figure 4.4b). A ~3Å shift in the C-terminal loop is accompanied
by the ~180 degree rotation of PHE476 in the pseudo-apo simulation which allows for this
ligand to be successfully docked. In the closest-to-active pose in the crystal structure
docking the ligand is found to occupy a pocket created between the C-terminal loop and
the G helix, resulting in a conformation where the SoM is 4.2Å from the reactive oxygen.
In the pseudo-apo simulation, shifting of the C-terminal loop causes a closure of this pocket
and causes the ligand to bind on the opposite side of the C-terminal loop where the SoM is
within 3.7A of the reactive oxygen and at a more favorable angle to the reactive oxygen.
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Figure 4.4: Conformational adaptation in the pseudo-apo simulation that allows for
successful docking of 9-cis-retinoic acid and torsemide. The true SoM for each ligand has
been denoted with a sphere. Compared to the flurbiprofen-bound crystal structure (shown
in dark grey sticks and cartoon), several residues and the C-terminal loop adapt to allow
for ligand binding. In the case of 9-cis-retanoic acid (a), LEU208 and PHE 476 rotate to
allow for the ligand to fit into a bioactive conformation. Furthermore ASP293 rotates into
a position to allow a potential hydrogen bond to the imidazole ring. In the case of torsemide
(b), a ~180º rotation of the side chain and a >3Å shift in the C-alpha position of PHE 476
was observed, allowing for a bioactive conformation of torsemide that was not observed in
the crystal structure. This shift closes a pocket between the C-terminus and the G helix (not
shown). The closest-to-active pose found in the crystal structure docking was found to
occupy this pocket. Closure of this pocket allows for an alternative ligand conformation to
be found in the pseudo-apo ensemble that is consistent with the known SoM of torsemide.
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4.3.3.2 Final Ensemble Selection
While, the inclusion of a variety of binding site conformations may be essential for
docking of large and diverse ligand libraries such as the one tested here, an ensemble of
several hundred members is both cumbersome and redundant; therefore the pseudo-apo
ensemble was further refined.
A docking filter was used to select the most relevant conformations from the initial
ensembles. Using a subset of 14 ligands and the fitness function described in the Methods
section, the top-6 structures from the pseudo-apo ensemble were selected as the final
ensemble members. The fitness scores, RMSD to the crystal structure, as well as the
binding site volume are shown for each member of the ensemble in Table 4.1.

109
Table 4.1: Calculated fitness score, overall RMSD to 1R9O crystal structure and binding
site volume of selected ensemble members. The volume of the binding site over the
course of the trajectory calculated using POVME
Structurea

Fitness

RMSD

Binding

Score

to

Site

Crystal Volume
PA 97

2.66

1.18

361

PA 19

2.58

1.19

393

PA 66

2.58

1.02

422

PA 1

2.55

1.12

836

PA 25

2.53

1.18

363

PA 91

2.51

1.08

411
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The 14-ligand training set was initially docked to all protein structures (Figure A1).
Although some individual members of the ensemble perform worse than the crystal
structure alone, taken together, ensemble docking shows significant improvement over
docking to the crystal structure alone. The crystal structure successfully docked only half
of the 14-ligand test set whereas the pseudo-apo ensemble docked successfully 13 out of
14 compounds into the top-5 protein structures alone (Figure 4.5). The remaining ligand,
2-oxoquazepam was successfully docked to the 34th ranked structure.
The selected ensemble members were found to be structurally diverse and to cover
a significant portion of the conformational space sampled by the MD simulation according
to the PCA (Figure 4.3). Compared to randomly selected ensembles of the same size, the
filtered ensemble provides considerable improvement in the docking results in the top-3
positions and slight improvement in the overall prediction success (Table 4.2). The
improvement over random selection indicates that the pre-filtering procedure aids in the
isolation of protein conformations relevant for docking.
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Figure 4.5: A visual representation of the docking performance in a) the crystal structure,
b) the pseudo- ensemble using the 14-ligand subset. Ligand ranking is indicated by the
shade of red, lighter regions indicate highly ranked poses, while black indicates that no
pose was found in which the true SoM was within a reactive distance to the oxygen on the
heme. The rank of the protein structure according to the fitness function is shown on the
far right hand side for the pseudo-apo ensemble.
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4.3.4 Ensemble Docking
Following the selection of the 6-member pseudo-apo ensemble, we used Vina to
dock all 73 compounds in the data set to each member of the ensemble. Compared to the
crystal structure alone, the ensemble offered significant improvement in the top-1, top-2
and top-3 positions and in the overall docking success (Table 4.2).
The more diverse binding pockets of the mixed ensemble are likely responsible for
the significant improvement in the overall docking success. The increase in accurate
predictions in the top-1, top-2 and top-3 positions, while significant, does not match the
improvement in overall docking success. The increased binding pocket diversity in the
ensemble is likely the reason that more compounds can be successfully docked, however,
this diversity can also result in a higher number of alternative ligand poses, making the
identification of true positive poses more challenging for the docking scoring function.
This is one possible reason that the individual increase in the top-1, top-2, and top-3
positions is not as drastic as in the overall docking performance.
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Table 4.2: Comparison of various methods for predicting SoMs in the top-1, top-2, and
top-3 positions.
X-ray structure aloneh
a
Random
SMARTCyp Vina
Vina
+ Vina+
Aloneb
Alonec
SMARTCypd SMARTCyp
+ QSARe
Top-1
12%
44%
21%
38%
49%
Top-2
24%
59%
27%
53%
56%
Top-3
38%
68%
37 %
60%
63%
% docked
64%
Gamma
0.0g
Pseudo-apo Ensemblei
Vina Alonef
Vina
+ Vina+
SMARTCy SMARTCy
p
p+ QSAR
Top-1
44%
55%
88%
[28 ±6.5%]
Top-2
58%
77%
96%
[37 ±5.7%]
Top-3
67%
88%
96%
[48± 7.0%]
% docked
96%
Gamma
[92±1.7%]
23.5
a

Percentage of correctly predicted SoMs if a heavy atom was chosen at
random for each ligand.
b
Percentage of correctly predicted SoMs using SMARTCyp only.
c
Percentage of correctly predicted SoMs using Autodock Vina alone. A
prediction was considered “correct” if the true SoM was within 4.0Å in the
top-1, top-2 or top-3 ranked docking poses, respectively.
d
Percentage of correctly predicted SoMs using a combination score
comprised of the Vina score and the SmartCyp score, see Methods section for
full details.
e
Percentage of correctly predicted SoMs using the modified QSAR model
that includes the poses provided by Vina docking and the reactivity scores
from SMARTCyp.
f
Bracketed values represent the percentage of successfully docked
compounds when the protein structures that comprised the ensembles were
chosen at random. These values represent the average and standard deviation
over three randomly selected protein sets.
g
Although a gamma (γ) of 0 is selected, the omission of some atoms due to
failure to find both a successful docking pose and SMARTCyp score can
result in slightly different rankings using the CS versus SMARTCyp. These
differences were caused by the inability to find a successful docking pose,
therefore an atom may be ranked in SMARTCyp but not the combination
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approach, which can result in slight changes in the overall rankings as
observed in the crystal structure.
h
Binding poses were identified using docking with AutoDock Vina to the xray structure of CYP2C9 only.
i
Binding poses were identified using docking with AutoDock Vina to an
ensemble of proteins structures generated by an MD simulations based on the
pseudo-apo form of CYP2C9 (holo x-ray structure with co-crystallized ligand
removed).
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4.3.5 Combining Docking and SMARTCyp
We hypothesized that SoM predictions could be further improved by combining the
structural data from docking and the ligand-based reactivity predictions from SMARTCyp.
For instance, let us assume that SMARTCyp incorrectly predicts a given atom as the true
SoM; although the incorrectly predicted atom may be a highly reactive, it may not be a
structurally feasible SoM based on its binding conformation. For example, it may be part
of a bulky group that cannot easily fit close to the reactive oxygen of the heme. By
including contributions from both docking and SMARTCyp, such atoms could be reranked or even eliminated as possible SoMs, resulting in improved predictions.
The optimized gamma value can offer insight about the individual contributions
of docking scoring and SMARTCyp to the overall ranking of the SoM; a low gamma
suggests that SMARTCyp dominates the calculated CS and docking only provides a
minor contribution, a gamma of around 10 would suggest approximately equal
contributions of both docking and SMARTCyp, and a large gamma would suggest that
docking dominates the CS function.
In the crystal structure, the optimized gamma value of 0.0 suggests that the results
are entirely dominated by the SMARTCyp rankings of the compounds. On the other
hand, the gamma score for the pseudo-apo ensemble is 23.5, suggesting that docking
scores are a major contribution to the overall CS ranking. There are several reasons for
this discrepancy in gamma scores. Most notably, in the pseudo-ensemble the rankings of
SMARTCyp and docking are approximately equal in the top-3 positions (~65%). This
suggests that both docking and SMARTCyp have approximately equal ability to
contribute to the final ranking. However, almost all compounds can be successfully
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docked to the ensemble, indicating that docking has the potential to further improve SoM
prediction above the ~65% observed with either approach individually. This is in
contrast to the crystal structure where docking has a significantly lower percentage of
compounds ranked in the top-3 (~45%) and also a lower overall docking success (~65%),
thus a less significant potential to contribute to the overall CS ranking.
In Figure 4.6, we provide some specific examples of how CS ranking in the
pseudo-apo ensemble improved SoM prediction in various compounds. In some
compounds, such as galangin, the contribution of the docking score was essential for the
top-1 CS ranking of the compounds (Figure 4.6a), whereas in others, like terbinafine, it
was the SMARTCyp (Figure 4.6b) score that was the determining factor. SMARTCyp
and docking did not rank the same ligands in the top-3 positions as was seen with
galangin and terbinafine. These differences allowed for approximately 10% improvement
in the CS ranking. However, the most intriguing cases were those in which different
rankings of individual atoms by SMARTCyp and docking led to a synergistic ranking
effect. In these cases, the CS ranking of the true SoM was higher than in either approach
individually. Suprofen, for example shows this trend (Figure 4.6c). Suprofen and other
ligands where there was a synergistic effect accounted for the remaining ~10%
improvement in the CS ranking is as compared to either method alone.
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Figure 4.6: The combined score (CS) versus docking and SMARTCyp scores individually
of the top-3 atoms as ranked by the CS. The top-ranked docking pose is shown on the left
of each panel and the bioactive pose is shown in orange on the right. In panel a, the top-
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ranked pose is the bioactive pose, thus only a single pose is shown. True SoMs have been
denoted in the text with a star and in the structures as an orange sphere. a) In some cases
the docking score is the determining factor for the overall CS ranking of the true SoM. In
fluvistatin, for instance, in the top ranked docking pose the true SoM, C25, was the atom
nearest to the reactive oxygen of the heme. Even when combined with a poor SMARTCyp
score, the favorable docking score of this pose allowed this atom to be ranked 1 st overall.
In other cases, SMARTCyp is crucial for the ranking using CS. In the case of mestranol,
the top-ranked docking pose places C10 and C14 nearest to the reactive oxygen (b).
However, these atoms were ranked poorly by SMARTCyp (4th and 5th, respectively). The
top-ranked bioactive pose (c) had a docking score that was only slightly less favorable than
the top ranked pose, and thus when combined with the SMARTCyp scores, wherein the
true SoM was ranked first, the overall CS ranking placed the true SoM in the top-1 position.
In some cases there was a synergistic outcome using the CS. In GV150526, SMARTCyp
incorrectly predicts the SoM as C3, however the docking results suggest that the
conformation leading to metabolism of C3 is unfavorable (ranked 15th overall). The overall
top-ranked pose (d) incorrectly predicts O14 as the true SoM, however this atom was not
favorably ranked using SMARTCyp. The top-ranked bioactive pose (e) ranks the true SoM
4th overall and SMARTCyp ranks this atom 2nd overall. Combining these predictions leads
to the true SoM, C20, being ranked 1 st overall.

119
Although using a combination approach in the pseudo-apo ensemble improved
performance over either SMARTCYP alone or docking alone, and all approaches tested
on the crystal structure alone, we hypothesized that using Quantitative Structure-Activity
Relationship (QSAR) modeling could improve the separation between active and inactive
docking poses and further improve SoM prediction in the top-1, top-2, and top-3
positions.

4.3.6 Ranking CS data using QSAR
QSAR is a computational method that derives statistical relationships between
sets of descriptors, typically ligand properties, and a set of values, typically the biological
activities of the target ligands. We hypothesized that there were certain key ligand
features, along with the spatial orientation of those features, which could distinguish
between active and decoy docking poses, and that QSAR statistical modeling could be
used to identify those features. By assigning a favorable score to active poses as
compared to decoy poses, we aimed to train a model to preferentially select active ligand
poses.
However, in addition to protein-ligand interactions, for CYP metabolism the
reactivity of a chemical group is an additional critical factor to determine the potential
SoM of a ligand. As pseudo-receptor QSAR programs, such as RAPTOR, do not directly
incorporate this factor, we modified RAPTOR to include SMARTCyp scores as a
descriptor in the modeling process. Using this modified QSAR approach, we were able to
significantly improve SoM predictions (Table 4.2 - Vina+SMARTCyp+QSAR column).
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Compared to SMARTCyp alone, docking alone, or the combined approach using
SMARTCyp and docking (CS), re-ranking atoms using QSAR proved to be far superior.
For example, the QSAR model based on the docking results from the pseudo-apo
ensemble was able to predict the correct SoM in 88% and 96% within the top-1and top-2
positions, respectively.
For several compounds the QSAR approach drastically improved the ranking of
the true SoM in comparison to the other methods tested (Figure 4.7). For instance, for
etodolac (Figure 4.7a and 4.7b) none of the other methods tested accurately predicted the
true SoM, C13, within the top-3 positions. However, using QSAR, the top ranked pose
placed the true SoM within 4.0Å of the reactive oxygen. Notably, this pose was very
poorly ranked using docking (10th overall). In other compounds, such as 17 alphaethinylestradiol (Figure 4.7c and 4.7d), the QSAR score offered incremental
improvements within the top-3 ranked positions. In this compound, both docking and
SMARTCyp were unable to rank the true-SoM within the top-3 positions. While the CS
method improved the ranking to the top-2 position, QSAR ranked the true SoM at the
top-1 position.
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Figure 4.7: Examples of compounds in which the QSAR method improves SoM prediction
over other tested methods. In the left column is the pose selected by the QSAR model and
in the right column is the top-ranked docking pose, in both cases the true SoM has been
shown in an orange sphere. The transparent white sticks represent the conformation of the
crystal structure. In the case of Etodolac, the top ranked QSAR and top-ranked docking
pose both have the true SoM oriented towards the reactive oxygen, but the QSAR pose
selects the structure in which the SoM is within a reactive distance (a and b). For17 alphaethinylestradiol, the QSAR model selects a pose that is completely inverted (c) from the
top-ranked docking pose (d). In both cases, the QSAR model places the known SoM in the
top-1 predicted position. Notably, in all cases successful ligand docking requires a
significant rearrangement of the binding site residues, as neither of these compounds could
be successfully docked to the crystal structure.
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One remaining limitation for the success of the QSAR model was the overall
docking success. In other words, assuming that an active pose was sampled during the
docking process, the QSAR model was nearly always able to identify the true SoM
within the top-3 positions. In the crystal structure for instance, the QSAR model
accurately predicted the SoM within the top-3 positions for all but one of the compounds
for which an active docking pose was obtained. For the pseudo-apo ensemble, all
compounds with an active docking pose were predicted within the top-2 ranked SoM.
Table 4.3 represents the QSAR results in isolation, i.e. only ligands for which
active docking poses were found are considered. In this situation, 91%, 100% and 100%
of the known SoMs are correctly predicted when the pseudo-apo ensemble was used for
docking within the top-1, top-2 and top-3, respectively. These percentages are slightly
lower when the crystal structure was used for docking, i.e., 77%, 87%, and 98%, for the
top-1, top-2, and top-3 positions, respectively.
While the QSAR model using the results from docking to the crystal structure was
severely limited by the quality of the docking process, the pseudo-apo docking set was
able to generate active poses for most ligands, allowing the subsequent QSAR model to
predict the known SoM in the top-2 positions in 96% of all cases.
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Table 4.3: QSAR SoM Rankings of ligands with an active docking pose.

QSAR Model
X-ray
Pseudo-apo
Ensemble

Fraction of Ligands with
Total Number of Active
Rank
Ligands
Top 1
Top 2
Top 3
0.77
0.87
0.98
47
0.91

1.00

1.00

70
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Over-fitting can be a concern in QSAR modelling, so the results for the test and
training set of the QSAR models were compared (Table 4.4). Similar to Table 4.3, only
those ligands for which an active docking pose was found are included in the
comparisons. For the x-ray structure, there was little differences between the two sets;
the training and test set had approximately the same fractions in the top-1, top-2, and top3 positions. For the pseudo-apo ensemble, the prediction accuracy of the test set
exceeded that of the training set, where the SoM of all ligands was correctly predicted in
the top-1 position. This indicates that the chemical space of the test set was wellcovered by the training set, and that the model has high predictive power for future
compounds within the space modeled.
Additionally, as the RAPTOR QSAR package generates a pseudo-receptor model
of the protein binding pocket around the ensemble of ligand poses, we visually compared
the QSAR model with the members of the pseudo-apo structural ensemble, a
representative example is shown in Figure 4.8. As shown, there is significant agreement
between the protein structure and the RAPTOR model. Where the model predicts
hydrophobic properties, the protein residues are mainly hydrophobic, such as LEU 366
and 361, and PHE 100, 114, and 476. Hydrophilic residues such as ARG 108, ASN 204,
and ASP 293 are collocated with hydrophilic features of the RAPTOR pseudoreceptor. PHE 100 and 114 both appear to be able to engage in different types of
interactions, as they are co-located with both hydrophobic and hydrophilic features,
indicating that π stacking interactions might play an important role in the binding pocket.
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Table 4.4: Comparison of QSAT Test and Training Sets.

QSAR Model
X-ray, training
X-ray, test
Pseudo-apo, training
Pseudo-apo, test

Fraction of Training Set
Total Number of
Ligands with Rank
Active Ligands
Top 1
Top 2
Top 3
0.76
0.88
1.00
33
0.79
0.86
0.93
14
0.88
1.00

1.00
1.00

1.00
1.00

51
19
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Figure 4.8: The QSAR model of the pseudo-apo data set. The binding site residues (a)
and pseudo-receptor (b) with 90º rotation (c) generated by RAPTOR. The pseudo-receptor
RAPTOR models are colored by property, with red representing hydrogen bond acceptors,
blue hydrogen bond donors, and brown and yellow as hydrophobic regions.
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4.4 CYP2C9 Conclusions
In this study, we compared the ability of ligand-based, structure-based, and
combination-based approaches to predict the SoM in 73 diverse CYP2C9 substrates. Of
all individual methods tested, docking was found to have the poorest performance.
Whereas ensemble docking showed a significant improvement over docking to the crystal
structure alone, at most 38% of the compounds were ranked in the top-1 position using
docking. Using the SMARTCyp reactivity model alone, 42% of the compounds were
accurately prediction in the top-1 position. By combining the docking scores and
SMARTCyp scores prediction accuracy was improved in both ensembles, but not in the
crystal structure. Ultimately, we found that the inclusion of QSAR into the combination
approach resulted in significant improvement in prediction success and was the most
effective and accurate SoM prediction method tested in this work.
In all systems tested, the QSAR model was able to accurately predict, within the
top-3 positions, the SoM for nearly all ligands with an active pose. A key limitation to the
success observed with QSAR was the ability of docking to provide active poses, in other
words, poses in which the true SoM was within a reactive distance to the oxygen of the
heme. Using a pseudo-apo ensemble, we were able to find an active docking pose for
nearly all ligands tested. To set our results in perspective, a recent study of currently
published methods found that accurate predictions in the top-2 positions range between
68-87%, on average, across various CYP isoforms 17. In the same study, the highest
prediction rate achieved for CYP2C9 was 87% in the top-217. Using our approach we
achieved an accurate prediction rate of 96% in the top-2 positions, albeit using a
different, dataset.
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Our promising results in CYP2C9 represent a step towards improved and highly
accurate SoM predictions in CYP enzymes. While in the current study we tested
substrates of CYP2C9, we believe that the proposed method will be of use in broader
ligand datasets and also will be applicable to different CYP isozymes.

4.5 Extension of method to other CYP Isozymes
The general ligand preparation procedure for the other CYP isozymes was identical
to the method used to prepare the CYP2C9 set. The size of the ligands sets for the CYPs
is as follows: 1A2 (271 Ligands), 2A6 (105 Ligands), 2B6 (151 Ligands), 2C8 (141
Ligands), 2C19 (218 Ligands), 2-D6 (270 Ligands), 2E1 (145 Ligands), 3A4 (475 Ligands).
The rest of the methods used to generate the SoM prediction models follow the same
procedure as section 2 of this chapter with two major exceptions.
The first change is with regards to the ligands used to select the representative
protein ensemble members. For 2C9, these ligands were manually selected. For the other
data sets, this process was automated. The ligand sets were clustered based on similarity
to select structurally diverse ligands. Generally, the size of the diverse selected was set to
be approximately 10-20% of the total ligand set. This guided selection process was used
for all remaining eight CYP isozymes. Similarly, for 2C9 the initial selection of the test
and training sets was random. This random set was then manually curated for coverage of
the chemical space of the ligand set. This process was also automated for the other ligand
sets using the same clustering method used to select the ensemble selection set, only with
slightly larger number of clusters. This process typically resulted in test sets of similar size
to the diverse selection set, 15-20% of ligand compounds.
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4.6 Results and Comparison for CYP Isozymes
As can be in Table 4.5, our models for all CYP isozymes produced highly reliable
predictions of CYP SoMs. The Top-1 prediction rates range from 79% for 1A2 to 97% for
2B6. The Top-3 prediction rates range from 85.2% for 2-D6 to 100% for 2C8. The average
prediction rate across all nine isozymes is 85% in the Top-1, 92% in the Top-2 and 93% in
the Top-3. It is important to note that overall docking accuracy was comparable to the
Top-3 percentage at 94%. Overall, and for each individual CYP isozyme, the same general
trend noticed for CYP2C9 was observed: if an active docking pose for a ligand can be
found, the QSAR model is generally able to place it in one of the top spots.
To investigate this issue, a secondary model was built for several of the CYP
isozymes with the lowest docking accuracy, including CYP2-D6. For these secondary
models, those ligands for each CYP isozyme which failed to find an active docking pose
in the initial model were used as the screening ligands for a repeat of the protein ensemble
member selection process. In general, most (over 90%) of the failed ligands successfully
docked to an ensemble member at this stage. In addition, there was significant overlap
between the original protein structure ensembles and the newly selected ensembles. The
new structures were added to the original protein ensembles, and the rest of the method
was repeated.
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Table 4.5: SoM Prediction for Nine Cyp Isozymes
Cyp Isozyme

Number of
Compounds

Succesful
Docking %

Top-1

Top-2

Top-3

1A2

271

93

79

90

91

2A6

105

94

87

93

93

2B6

151

99

97

99

99

2C8

141

100

94

100

100

2C9

226

96

88

96

96

2C19

218

88

80

87

88

2D6

218

87

80

84

85

2E1

270

96

81

89

91

3A4

475

94

80

90

92
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However, after the new models were completed, there was no significant change in
overall docking accuracy or final prediction rates of the models. Comparing which ligands
were successfully docked for each model, while most ligands docked successfully to both
models, some ligands docked successfully to only one model, while some docked to neither.
This last set was of particular interest, as many of these ligands docked successfully in the
ensemble selection process. When the results of the ensemble selection process were
further analyzed, we found a common characteristic: The ligands that successfully docked
in the ensemble selection stage did so with low ranks. We therefore concluded that the
docking scoring process was a weakness in our method, as it preferred non-active poses
for some ligands.
Even with this issue with the docking process, our results compare favorably with
the top methods in the field. Table 4.6 is a comparison of the Top-2 prediction percentages
for our method, along with Xenosite17, RS-Predictor12, and SmartCYP2, along with the
random prediction rate. The major difference between CyPredict and the other methods is
the use of structure-based information. CyPredict uses both ligand-based and structurebased methods, while the other methods are purely ligand-based, using quantum chemical
and topological descriptors. Our method produced the highest successful prediction rate
for seven of the nine tested CYP isozymes, with the exceptions being 2C19 and 2-D6. For
CYP2C19, our rate was 87% as compared to 89% for Xenosite. For CYP2-D6, our rate
was 84% compared to 89% for Xenosite and 86% for RS-Predictor. For the other isozymes,
our method performed 3% to 15% better than the next best method, and our average
prediction rate was 92% compared to 87% for Xenosite, 84% for RS-Predictor, and 82%
for SMARTCyp.
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Table 4.6: Comparison of Cyp SoM Prediction Methods
Method

1A2

2A6

2B6

2C8

2C9

2C19

2D6

2E1

3A4

Ave.

Lill

90.0

93.0

98.7

100

96.0

87.2

83.7

89.0

90.0

92.0

Xenosite17

87.1

85.7

83.4

88.7

86.7

89.0

88.5

83.5

87.6

87.0

RSPredictor12

83.4

85.7

82.1

83.8

84.5

86.2

85.9

82.8

82.3

84.3

SMARTCyp2 80.0

86.0

77.0

83.0

84.0

86.0

83.0

82.0

78.0

82.1

Random

31.9

24.8

22.6

22.2

20.2

21.1

36.5

21.0

25.3

26.0
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Another key factor in these comparisons is the validation method for the models.
Xenosite used leave-one-out cross-validation, while RS-Predictor and SMARTCyp used
10-fold validation. These methods use multiple models with test sets of either one
compound (leave-one-out) or 10% of compounds (10%). In comparison, our test sets range
from approximately 50% to 90% of our ligands. These large test sets indicate that our
models have retained significant predictive power while avoiding possible overfitting of
the data.
4.7 Conclusions
With these last studies, we have shown that we are successfully able to extend our
model to other CYP isozymes beyond 2C9. Our models compare favorably with the
current best-performing CYP SoM prediction techniques, and in several cases significantly
outperform them. In addition, we have identified a specific area of concern to focus on for
improving our methods: increasing docking accuracy. Currently, this is the weakest
portion of our method, as the pseudoreceptor modeling process is generally able to
correctly select active ligand poses if one has been generated by the docking process.
Beyond improving docking, any further improvements in the process will require more
complex calculations, such as QM/MM methods, as the second largest source of error we
found is in the SMARTCyp scoring process.
In addition, the completed CYP models are being made freely available to academic
users for SoM prediction through a webserver using the Nanohub platform. 18 The server
will be available at https://nanohub.org/tools/cypredict/.
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CHATER 5. FUTURE DIRECTIONS

5.1 Research Summary
The overall goal of my research was the application and development of the
advancement of combined ligand-based and structure-based techniques, namely
pseudoreceptor-based methods, with a focus on surface-based pseudoreceptors. While the
goal of pseudoreceptor methods is to produce a protein-like structure to interact with
ligands, there has been a lack of use of protein structural data in the guiding of the creation
of the pseudoreceptors. In Chapter 2, analysis of the interaction surface between protein
crystal structure and co-crystallized ligand for the refined set of the PDBbind database was
presented. These surfaces represented the ideal pseudoreceptor, as they mapped the true
interactions of protein and ligand, and the analysis showed that the majority of proteinligand interactions can be mapped by a few of Gaussian-based descriptors that have
parameters that fall into a small range of values. In Chapter 3, a means of tuning surfacebased pseudoreceptors to accurately replicate protein binding pocket topology as from
known binding ligands will be presented.
In Chapter 4, I will discuss the implementation of the refinement of our group’s
previous work on SoM prediction, which includes the use of a modified version of the
RAPTOR pseudoreceptor package. The modification was the inclusion of reactivity scores
from the SMARTCYP package as term in the RAPTOR scoring function. The
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motivation for the inclusion of RAPTOR was as a means of generating a model which
could reliably select binding poses with the known SoM close to the heme of CYP. This
method was implemented as a means to counteract the difficulties arising from the large
number of poses generated by the ensemble docking process. The initial modeling was
performed on CYP2C9, but was later extended to eight other CYP isozymes. In this final
chapter, we will discuss several possible methods for continuing or improving upon the
research discussed in this thesis.

5.2 Pseudoreceptor Method
To extend the work presented in Chapters 2 and 3, we have worked to implement a
new pseudoreceptor-based QSAR package based on the RAPTOR package but with
improvements based on the insights presented in this thesis. Significant progress has been
made on this new computational tool, but it has not yet reached completion. In addition to
improvements to the pseudoreceptor method, we have also chosen to move to Python from
the C-based languages for the primary programming language. Python is well-suited for
file and data management tasks, but lacks speed for intense computations. We have used
weave to integrate fast C code for those portions of the code with large numbers of complex
calculations. The method alterations are primarily focused on a Correlated Mutli-surface
Model and an altered machine learning and scoring method.
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5.2.1 Correlated Multi-surface (CMS) Model
After our analysis in Chapter 3, where we determined that a single iso-surface is
unable to represent the flexible binding pocket of a protein for diverse ligands, we
developed a CMS model. Our first thought was to simply use multiple independent isosurfaces of varying iso-level values.

Each iso-surface is generated from the ligand

occupancy values via the Marching Cubes algorithm. After consideration though, we had
a number of concerns with this process. With independent iso-surfaces, even regions where
the surfaces are very close together, the algorithm could have assigned sets of radically
different Gaussians to the surfaces, which is not realistic. If the shells are representing the
same region and conformation of a protein, they should have identical physico-chemical
(electrostatic, hydrophobic, hydrogen bond) properties. To address this, we decided to
correlate the iso-surfaces if they are physically close to each other.

To determine

correlation, for each vertex of each iso-surface, the closest vertex (as determined by
distance scaled by angle between the vertices) of every other iso-surface is found. If the
closest vertex is within a certain cut-off, the vertices are then linked to each other, which
is important when generating the initial Gaussians and in the genetic algorithm.
After generating and correlating our multiple iso-surfaces, we generate our initial
Gaussian regions via the following process. First, we determine the total strength of every
ligand atom’s interactions with every shell that contains that atom. (A shell contains a
ligand atom if the iso-level of that shell is lower than the occupancy value at that atom’s
coordinates.) This strength is determined by the same functions as used for the protein in
the PLSIA algorithm presented in Chapter 2. From the ten vertices with the largest value
for a property, one is randomly selected and a Gaussian is generated using random value
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parameters, with ranges determined from our previous work. This Gaussian is then mapped
to the surrounding surface, and a Gaussian region is determined. If the surface point where
the center of the Gaussian is correlated, this Gaussian is propagated to all correlated isosurfaces. All members of the Gaussian region are then excluded, and the ten strongest nonexcluded vertices are found and a new center chosen. This process repeats up to a
maximum number of iterations for all properties of all shells, with correlated regions
counting towards the maximum. In order to provide more diverse models, the maximum
number of iterations is randomly determined.

5.2.2 Scoring and Machine Learning
The Gaussian-mapped shells are then passed to the machine learning algorithm for
the creation of the final pseudoreceptor model. We have implemented the PyEvolve
genetic algorithm package with customized functions. We have implemented correlated
cross-over and mutation functions. In the cross-over function, the algorithm selects one
Gaussian from one of the parent models and then swaps that Gaussian and all its correlated
Gaussians with a set of correlated Gaussians of the appropriate physico-chemical property
from the other parent. This cross-over is also restricted by a distance cut-off between the
locations of centers of the Gaussians: only Gaussians located in the approximately the same
location may be swapped. The mutation function also works amongst correlated Gaussians.
The allowed mutations are addition, deletion, moving the center along a single edge of the
iso-surface, and change of Gaussian parameter (radius, amplitude, and angle). These
mutations are propagated to all correlated Gaussians, and correlated Gaussians are created
or deleted if necessary.
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After a certain number of steps, we export the top models from the genetic
algorithm to a Monte Carlo optimization algorithm along with the initial ligand
conformations from the alignment process.

In the Monte Carlo process, the ligand

conformations are allowed to translate as well as rotate. The best pose for each ligand
conformation, as scored using the same scoring function as in the genetic algorithm, is
returned to the pseudoreceptor program for all Monte Carlo models. The best scored pose
for each ligand conformation from amongst all the Monte Carlo models is identified and
selected. These poses are then used to generate a new pseudoreceptor model (new isosurfaces and genetic models) until a set number of iterations of the full process have been
completed, then the final predictions are generated.
These processes will be scored by computing the interaction between the fields
from the Gaussian surfaces directly with the ligand atoms. Typically, scores are computed
between the ligand atoms and the discrete grid points. This point-to-point pairwise scoring
not only creates a large number of descriptors which can lead to overfitting; it does not
replicate the surfaces found in actual protein-ligand interactions. With our process, instead
of each grid point being independent, regions of the iso-surface are linked by Gaussian
functions where the properties of the entire region are determined by the four 2-D Gaussian
parameters. We are currently scoring the Gaussians with a simple modified piece-wise
linear pairwise (PLP) scoring function combined with an electrostatic term.

The

electrostatics are computed by computing the pairwise Coulombic interaction between the
ligand atoms and the iso-surface vertices of electrostatic Gaussians. Hydrophobic, steric,
and hydrogen bond terms are calculated using a modified PLP function (Gehlhaar, 1995).
The PLP scoring function follows the general form shown in Figure 5.1, and is calculated
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between ligand atoms and the iso-surface vertices appropriate Gaussian regions, except the
steric term is calculated with the full iso-surface instead of Gaussian regions.

The

individual interactions are then scaled according the Gaussian value of the vertex.

5.3 CYP SoM Prediction
As illustrated in Chapter 4, we have achieved significant success with our algorithm
for the prediction of SoMs for a number of CYP isozymes, but we also feel there are
potential avenues to improve and extend the method. First, as mentioned previously, one
major issue is docking accuracy, which is typically less than 100% for the CYP isozymes.
Second, while we have tested the performance on a single CYP isozyme at a time, we have
not explored trying to predict SoM’s against multiple CYP isozymes simultaneously.

5.3.1 Docking Accuracy
As previously mentioned, with our method, if we can obtain an active docking pose,
the pseudoreceptor model can generally identify that pose. Therefore, the major source of
error for our models is in the docking process. We found that increasing the number of
protein ensemble members was not successful in remedying this issue. This is supported
by our studies of CYP2C9, where we found insignificant increase in model accuracy when
using more than six protein structure models. The other CYP isozymes seem to follow this
trend, adding structures above a certain minimum does not significantly improve docking
accuracy.
During our analysis of our results, we found the ligands that were not always
successfully docked often had active poses that were poorly ranked. Currently, we only
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take the top ten ligand poses into consideration, and the active poses for these ligands are
generally ranked close to ten if successfully docked at all. Therefore, to increase docking
accuracy, one possible solution is to increase the number of generated docking poses. This
is not an ideal solution, as this increases the number of poor poses for those ligands for
which we can find active poses in the top ten. This can eventually cause difficulties for the
pseudoreceptor modeling process. Another possible solution is iterating the docking
process. As we know from our previous studies, we can occasionally find active poses
from the difficult ligands. Therefore, if we run the docking process multiple times, an
active pose may be generated. As we would still only generate the top ten poses for each
iteration, the ratio of active to decoy poses should remain relatively constant, which should
theoretically be favorable to purely increasing the number of accepted poses. That is, while
both processes could decrease QSAR accuracy due to an increased number of docking
poses, the iterative process should have a better ratio of active to decoy poses, so long as
the docking scoring process is better than random and an equivalent total number of poses
are generated.. Extensive docking studies are needed to determine which method is
preferred, as it is dependent on both how likely we are to find an active pose at a given
rank, and how this changes when the total number of ranks is increased.

Another

alternative is an additional docking processing step where the poses are scored with a more
accurate function, such as MM/PBSA or MM/GBSA. While using more sophisticated
scoring function would increase the computational cost of docking, it might be possible to
maintain or reduce the number of necessary poses.
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5.3.2 CYP Selectivity
The percentage of approved drugs that the CYP isozymes, studied in this thesis,
metabolize was discussed in Chapter 4. The sum of these percentages is well above 100%,
which is indicative of one of the issues of metabolism: multiple metabolic pathways. In
our studies, we have only worked with known ligands for each CYP isozyme. While being
able to reliably predict where each isozyme will metabolize a ligand, it is also important to
be able to predict which isozymes will metabolize a given ligand.
In order to assess the ability of our method to address this problem, instead of using
a tailored ligand set for each isozyme, we will repeat our studies with a combined ligand
set formed from the individual isozyme sets. For each isozyme, those ligands that are not
known to be metabolized by that isozyme will have all their docking poses classified as
decoy poses. The selectivity of our method for each isozyme will then be determined by
analyzing the scores of the known ligands, most likely using a method such as a receiver
operating characteristic curve. This analysis would give a score of one if our method scores
all known metabolites ahead of all known inactive compounds, and gives a score of zero
for the reverse scenario.
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APPENDIX

This appendix contains supplementary tables S1-S11 for Chapter 3.
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Table A1: Protein systems and corresponding pdb codes

Protein System PDB Entries
1a94
HIV-PR
1aaq
1g2k
1g35
1gnm
1gnn
1gno
1hbv
1gwq
ERα
1gwr
1x7e
2p15
2q70
2qe4
2qgt
1b38
CDK - 20
1h00
1h0v
1h0w
1h07
1ke5
1pxm
1pnx
1pxp
1q8t
1q8u
1q8w
1rej
1stc
1vyz
1y91
1yds
1ydt
2uzn
2uzo
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Protein System PDB Entries
1q8u
CDK - 10
1q8w
1rej
1stc
1vyz
1y91
1yds
1ydt
2uzn
2uzo
1y91
CDK - 5
1yds
1ydt
2uzn
2uzo

Table A2: Occupancy Distribution of Estrogen Receptor
c-value

Fraction of surface points with target occupancy

1.4 0.001 0.072 0.183 0.167 0.153 0.126 0.096 0.073 0.044 0.026 0.017 0.015 0.008 0.009 0.006 0.002 0.001 0.002 0.000 0.000 0.000 0.000
2 0.000 0.012 0.052 0.083 0.102 0.122 0.128 0.112 0.106 0.081 0.074 0.045 0.029 0.018 0.016 0.008 0.005 0.005 0.002 0.000 0.000 0.000
2.5 0.000 0.002 0.028 0.033 0.041 0.067 0.091 0.103 0.118 0.111 0.103 0.090 0.084 0.050 0.027 0.020 0.014 0.012 0.003 0.002 0.000 0.000
3 0.000 0.000 0.016 0.030 0.016 0.017 0.044 0.068 0.081 0.104 0.122 0.115 0.111 0.095 0.077 0.045 0.027 0.017 0.009 0.005 0.000 0.000
Target

0 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A3: Cumulative Occupancy of Estrogen Receptor

c-value Cumulative Occupancy Fraction
1.4 1.000 0.999 0.927 0.744 0.577 0.424 0.298 0.202 0.129 0.085 0.059 0.042 0.028 0.019 0.011 0.005 0.003 0.002 0.000 0.000 0.000 0.000
2 1.000 1.000 0.988 0.936 0.854 0.751 0.630 0.502 0.390 0.284 0.203 0.128 0.084 0.055 0.036 0.021 0.013 0.008 0.003 0.000 0.000 0.000
2.5 1.000 1.000 0.998 0.969 0.936 0.895 0.827 0.737 0.634 0.516 0.406 0.302 0.212 0.128 0.078 0.051 0.031 0.017 0.005 0.002 0.000 0.000
3 1.000 1.000 1.000 0.984 0.954 0.939 0.922 0.877 0.809 0.729 0.624 0.502 0.387 0.275 0.180 0.103 0.058 0.031 0.014 0.005 0.000 0.000
Target

0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A4: Occupancy Distribution of HIV-PR
c-value Fraction of surface points with target occupancy
1.4 0.049 0.146 0.151 0.147 0.137 0.114 0.088 0.064 0.044 0.026 0.016 0.009 0.005 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
2 0.011 0.095 0.090 0.083 0.089 0.102 0.108 0.105 0.089 0.072 0.059 0.042 0.028 0.017 0.008 0.003 0.000 0.000 0.000 0.000 0.000 0.000
2.5 0.001 0.059 0.063 0.063 0.059 0.066 0.077 0.092 0.098 0.096 0.092 0.076 0.064 0.045 0.028 0.015 0.005 0.001 0.000 0.000 0.000 0.000
3 0.000 0.029 0.045 0.048 0.048 0.048 0.051 0.065 0.076 0.091 0.096 0.100 0.094 0.081 0.060 0.043 0.021 0.006 0.000 0.000 0.000 0.000
Target

0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A5: Cumulative Occupancy of HIV-PR
c-value Cumulative Occupancy Fraction
1.4 1.000 0.951 0.805 0.654 0.507 0.369 0.255 0.167 0.103 0.059 0.032 0.016 0.007 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
2 1.000 0.989 0.894 0.804 0.721 0.632 0.530 0.422 0.317 0.228 0.156 0.097 0.055 0.027 0.010 0.003 0.000 0.000 0.000 0.000 0.000 0.000
2.5 1.000 0.999 0.941 0.878 0.815 0.755 0.689 0.612 0.520 0.422 0.326 0.234 0.158 0.094 0.049 0.021 0.005 0.001 0.000 0.000 0.000 0.000
3 1.000 1.000 0.971 0.927 0.879 0.831 0.783 0.732 0.668 0.592 0.500 0.404 0.305 0.211 0.130 0.071 0.028 0.006 0.000 0.000 0.000 0.000
Target

0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A6: Occupancy Distribution of CDK-20

c-value Fraction of surface points with target occupancy
1.4 0.014 0.182 0.221 0.150 0.105 0.077 0.062 0.051 0.043 0.037 0.026 0.018 0.009 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
2 0.003 0.095 0.143 0.136 0.125 0.097 0.082 0.069 0.058 0.048 0.040 0.038 0.030 0.023 0.010 0.003 0.000 0.000 0.000 0.000 0.000 0.000
2.5 0.000 0.058 0.095 0.097 0.108 0.105 0.096 0.080 0.073 0.061 0.052 0.044 0.042 0.038 0.029 0.017 0.005 0.000 0.000 0.000 0.000 0.000
3 0.000 0.033 0.070 0.063 0.077 0.096 0.093 0.094 0.079 0.076 0.066 0.057 0.047 0.045 0.044 0.037 0.020 0.003 0.000 0.000 0.000 0.000
Target

0 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A7: Cumulative Occupancy of CDK-20
c-value Cumulative Occupancy Fraction
1.4 1.000 0.986 0.804 0.583 0.433 0.328 0.251 0.189 0.138 0.095 0.058 0.031 0.013 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
2 1.000 0.997 0.902 0.759 0.623 0.499 0.402 0.320 0.251 0.193 0.146 0.105 0.067 0.037 0.014 0.004 0.000 0.000 0.000 0.000 0.000 0.000
2.5 1.000 1.000 0.942 0.846 0.750 0.642 0.537 0.440 0.361 0.288 0.227 0.175 0.131 0.089 0.051 0.022 0.005 0.000 0.000 0.000 0.000 0.000
3 1.000 1.000 0.967 0.897 0.834 0.757 0.662 0.569 0.475 0.395 0.319 0.253 0.196 0.149 0.104 0.060 0.023 0.003 0.000 0.000 0.000 0.000
Target

0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A8: Occupancy Distribution of CDK-10
c-value Fraction of surface points with target occupancy
1.4 0.043 0.160 0.188 0.153 0.102 0.072 0.058 0.045 0.043 0.037 0.032 0.026 0.019 0.010 0.007 0.003 0.002 0.000 0.000 0.000 0.000 0.000
2 0.022 0.088 0.112 0.133 0.116 0.097 0.076 0.060 0.052 0.048 0.042 0.041 0.035 0.030 0.023 0.013 0.008 0.003 0.001 0.000 0.000 0.000
2.5 0.012 0.055 0.072 0.088 0.106 0.102 0.087 0.076 0.064 0.053 0.052 0.049 0.043 0.043 0.035 0.030 0.019 0.010 0.004 0.000 0.000 0.000
3 0.008 0.034 0.050 0.060 0.072 0.084 0.095 0.082 0.074 0.067 0.058 0.054 0.053 0.050 0.047 0.042 0.035 0.022 0.010 0.002 0.000 0.000
Target

0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A9: Cumulative Occupancy of CDK-10
c-value Cumulative Occupancy Fraction
1.4 1.000 0.957 0.797 0.608 0.456 0.354 0.282 0.223 0.178 0.135 0.098 0.066 0.040 0.021 0.012 0.005 0.002 0.000 0.000 0.000 0.000 0.000
2 1.000 0.978 0.890 0.778 0.645 0.529 0.432 0.356 0.296 0.244 0.196 0.154 0.112 0.077 0.047 0.024 0.012 0.004 0.001 0.000 0.000 0.000
2.5 1.000 0.988 0.933 0.860 0.772 0.666 0.564 0.477 0.401 0.338 0.284 0.232 0.183 0.140 0.097 0.063 0.033 0.014 0.004 0.000 0.000 0.000
3 1.000 0.992 0.958 0.908 0.848 0.776 0.692 0.597 0.515 0.441 0.374 0.315 0.261 0.208 0.158 0.112 0.069 0.034 0.012 0.002 0.000 0.000
Target

0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A10: Occupancy Distribution of CDK-5

c-value Fraction of surface points with target occupancy
1.4 0.080 0.168 0.154 0.126 0.098 0.073 0.056 0.050 0.045 0.036 0.034 0.032 0.022 0.012 0.007 0.004 0.002 0.000 0.000 0.000 0.000 0.000
2 0.040 0.102 0.100 0.100 0.100 0.093 0.079 0.068 0.056 0.050 0.045 0.042 0.036 0.032 0.027 0.017 0.008 0.004 0.001 0.000 0.000 0.000
2.5 0.024 0.068 0.065 0.075 0.081 0.081 0.086 0.080 0.074 0.066 0.055 0.049 0.046 0.040 0.034 0.034 0.025 0.012 0.005 0.001 0.000 0.000
3 0.013 0.045 0.049 0.051 0.060 0.065 0.071 0.078 0.080 0.077 0.074 0.063 0.054 0.049 0.043 0.041 0.042 0.030 0.012 0.003 0.000 0.000
Occupa
ncy
0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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Table A11: Cumulative Occupancy of CDK-5
c-value Cumulative Occupancy Fraction
1.4 1.000 0.920 0.751 0.597 0.471 0.373 0.300 0.244 0.194 0.149 0.114 0.080 0.048 0.026 0.014 0.007 0.003 0.000 0.000 0.000 0.000 0.000
2 1.000 0.960 0.858 0.758 0.658 0.558 0.465 0.387 0.318 0.262 0.212 0.167 0.126 0.090 0.058 0.031 0.014 0.005 0.001 0.000 0.000 0.000
2.5 1.000 0.976 0.908 0.843 0.768 0.687 0.606 0.520 0.441 0.367 0.301 0.246 0.196 0.151 0.111 0.077 0.043 0.018 0.006 0.001 0.000 0.000
3 1.000 0.987 0.941 0.892 0.842 0.782 0.717 0.646 0.568 0.488 0.410 0.336 0.273 0.219 0.171 0.128 0.087 0.045 0.015 0.003 0.000 0.000
Target

0.000 0.025 0.075 0.125 0.175 0.225 0.275 0.325 0.375 0.425 0.475 0.525 0.575 0.625 0.675 0.725 0.775 0.825 0.875 0.925 0.975 1.000
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